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ABSTRACT 
Background: Singletons born following assisted reproductive technology (ART) have adverse neonatal 
outcome compared to singletons born following spontaneous conception (SC). Moreover, the women 
undergoing ART are at an increased risk of hypertensive disorders in pregnancy (HDP) and placental 
complications.                            
Aim: To study the neonatal and maternal outcomes following the introduction of advanced techniques 
in ART.                     
Material and methods: All papers were population-based register studies in Sweden with cross linkage 
of the national ART registers and national health data registers. In paper III also Danish register data 
were included. Paper I Singletons born after blastocyst transfer (n=4819), singletons born after cleavage 
stage transfer (n=25,747) and singletons born after SC (n=1,196,394) were included. The main outcome 
was birth defects. Moreover, other neonatal and maternal outcomes were assessed. Paper II Neonatal 
and maternal outcomes in different cycle regimens in frozen embryo transfer (FET) (n=6297 in natural 
cycles, n=1983 in stimulated cycles, n=1446 in programmed cycles) were studied. FET was also 
compared to fresh embryo transfer and to SC. The primary outcomes were preterm birth (PTB, <37 
weeks), low birth weight (LBW, <2500 grams), HDP and postpartum hemorrhage (PPH, >1000 mL). 
Paper III Singleton pregnancies following transfer of vitrified blastocysts (n=3650) were compared to 
singleton pregnancies following slow-frozen cleavage stage transfer (n=8123) and fresh blastocyst 
transfer (n=4469). Main outcomes were PTB, LBW, macrosomia, HDP and PPH. Paper IV Singletons 
born following preimplantation genetic testing (PGT) (n=267) were compared to singletons born 
following in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) (n=55,355) and to SC 
(n=26,535). Main outcomes were PTB and LBW. Moreover, maternal outcomes and early childhood 
outcome were assessed.                                                   
Results: Paper I No difference in the rate of birth defects were observed between the groups. However, 
there was an increased risk of placenta previa and placental abruption following blastocyst transfer 
compared to transfer of cleavage stage embryos and SC. Paper II Programmed cycles were associated 
with a higher risk of HDP (adjusted odds ratio [AOR] 1.6-1.8), PPH (AOR 2.6-2.9), post term birth 
(AOR 1.6-2.0) and macrosomia (≥4500 grams) (AOR 1.4-1.6) compared to other cycle regimens. The 
rates of PTB and LBW were similar independently of cycle regimen. Paper III Transfer of vitrified 
blastocysts was associated with a higher risk of PTB (AOR 1.3). No other differences were found.    
Paper IV For PGT singletons no differences in PTB and LBW were observed in comparison to other 
IVF/ICSI singletons yet higher rates compared to SC. The early childhood outcomes were reassuring but 
should be interpreted cautiously due to few cases and short follow-up time.                
Conclusion: Blastocyst transfer is associated with a higher risk of placenta previa and placental 
abruption compared to cleavage stage transfer. Programmed cycles were associated with higher risks of 
HDP and PPH compared to other cycle regimens. The freezing technique or the embryo biopsy used for 
PGT do not seem to alter the neonatal and maternal outcomes.             
 
Keywords: blastocyst transfer, frozen embryo transfer, vitrification, preimplantation genetic testing, 
neonatal outcome, maternal outcome 
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SAMMANFATTNING PÅ SVENSKA 
Infertilitet drabbar 10-15% av alla par och idag föds i Sverige ca 5000 barn årligen 
efter assisterad befruktning (ART). ART innebär hantering av könsceller utanför 
kroppen och innefattar bl.a. provrörsbefruktning (in vitro fertilisering, IVF) och 
mikroinjektion ("intracytoplasmic sperm injection", ICSI). Det är sedan tidigare känt 
att barn födda efter IVF har en ökad risk för förtidsbörd och låg födelsevikt jämfört 
med barn födda efter spontan befruktning. Denna riskökning kan till stor del förklaras 
av den ökade risken för flerbörd efter IVF men ökade risker har även visats för barnen 
födda i enkelbörd. Sannolikt bidrar såväl behandlingstekniken som den 
bakomliggande infertiliteten till detta.  
 
Under senare år har flera nya tekniker införts. Vid blastocyståterföring har embryot 
odlats utanför kroppen i 5-6 dagar istället för i 2-3 dagar som tidigare varit rutin. Vid 
en färsk behandlingscykel återförs ett embryo i livmodern i samma cykel som ägget 
utplockas. I vissa fall väljer man dock att inte göra ett färskt återförande utan att frysa 
samtliga embryon. Väljer man att göra ett färskt återförande, fryses övriga embryon 
ned för att kunna tinas upp och återföras vid ett senare tillfälle. Vid en fryscykel kan 
embryot återföras i olika typer av cykler. Vid en naturlig cykel återförs embryot i 
kvinnans naturliga menscykel. Vid en stimulerad cykel stimuleras kvinnans 
äggstockar till en ägglossning varpå embryot återförs. Vid en programmerad cykel 
ges kvinnan läkemedel som förbereder livmoderns slemhinna att ta emot ett embryo 
utan att stimulera till ägglossning. Därtill har en ny frysteknik, vitrifiering med 
ultrasnabb nedfrysning av embryot, införts på bred front. Tidigare studier visar att 
graviditeter efter blastocyståterföring är behäftade med en ökad risk för förtidsbörd 
och, enligt en tidigare svensk studie, även med missbildningar i jämförelse med 
återförande av dag 2-3 embryon. Barn födda efter frysåterförande har visats ha en 
ökad risk för att födas "stora för tiden" i jämförelse med barn födda efter färska cykler 
och spontan befruktning. Kvinnor som blivit gravida efter IVF drabbas i högre 
utsträckning av hypertoni/havandeskapsförgiftning (preeklampsi) med störst risk för 
hypertoni/preeklampsi vid behandling med frysta/tinade embryon. Därtill har 
kvinnorna en ökad risk för placentakomplikationer så som föreliggande/lågt sittande 
moderkaka och moderkaksavlossning.   
                       
Syftet med denna avhandling var att studera utfallet för barnen och deras mödrar efter 
introduktionen av avancerade tekniker inom ART. Endast barn födda i enkelbörd 
inkluderades. Samtliga delarbeten utfördes som populationsbaserade registerstudier i 
 
Sverige med korskörning av de nationella registren för assisterad befruktning mot 
nationella hälsoregister. I den tredje studien inkluderades även danska registerdata.  
 
I delarbete I jämfördes barn födda efter blastocyståterföring med barn födda efter 
återförande av dag 2-3 embryon och spontan befruktning. Studien visade ingen 
skillnad i missbildningsfrekvens men däremot en ökad risk för föreliggande/lågt 
sittande moderkaka och avlossning av moderkakan efter blastocyståterförande. 
Delarbete II visade att utfallet varierar med vilken typ av fryscykel som används och 
att riskerna för mor och barn var störst efter programmerad cykel med ökad risk för 
så väl hypertoni/preeklampsi och stor blödning i samband med förlossning samt även 
för överburenhet och stora barn. I delarbete III jämfördes de två frystekniker som 
används idag, vitrifiering och den äldre tekniken, "slow-freezing", och resultaten 
visade att frystekniken inte påverkar utfallet för varken mor eller barn. I delarbete IV 
jämfördes barn födda efter preimplantatorisk genetisk testing (PGT) mot barn födda 
efter IVF/ICSI och spontan befruktning. PGT erbjuds par som är drabbade av eller 
bärare till en genetisk sjukdom och möjliggör återförande av ett embryo som inte bär 
på denna sjukdom. För att utföra PGT krävs dels IVF eller ICSI men även 
embryobiopsi där en eller två, ibland upptill tio celler, avlägsnas från embryot och 
analyseras för den specifika genetiska sjukdomen. Resultaten i delarbete IV talar för 
att embryobiopsin som används vid PGT inte påverkar utfallet för mor och barn. Även 
långtidsutfallen, inkluderande bl.a. astma, psykiatrisk sjuklighet och cerebral pares, 
för PGT barnen var betryggande. Dock skall resultaten tolkas med försiktighet p.g.a. 
få fall men även p.g.a. kort uppföljningstid.    
  
 
ABBREVIATIONS AND DEFINITIONS  
ADHD Attention deficit hyperactivity disorder 
AID Artificial insemination of donated sperm 
AOR Adjusted odds ratio 
Array-CGH Array-comparative genome hybridization 
ART Assisted reproductive technology; includes treatment where 
human gametes are handled outside the body to achieve a 
pregnancy 
ASD Autism spectrum disorders 
ATC codes Anatomic Therapeutic Chemical codes; a drug classification 
system that classifies the drugs according to the organ or system 
on which they act 
BMI Body mass index 
CDC Centers for Disease Control and Prevention 
CI Confidence interval 
CL Corpus luteum; a mass of cells that forms in an ovary following 
ovulation and is responsible for the production of mainly 
progesterone during early pregnancy. 




Use of fertility medication to induce ovulation of several 
ovarian follicles 
CVD Cardiovascular disease 
DNA Deoxyribonucleic acid 
EIM European IVF Monitoring Consortium 
ESHRE European Society of Human Reproduction and Embryology 
EUROCAT European network of population-based registers for 
epidemiological surveillance of birth defects 
FET Frozen embryo transfer 
FISH Fluorescence in situ hybridization 
FSH Follicle stimulating hormone 
GnRH Gonadotropin releasing hormone; a hormone released from the 
hypothalamus and responsible for the release of follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) from 
the pituitary 
hCG Human chorionic gonadotropin 
hMG Human menopause gonadotropin 
 
HDP Hypertensive disorders in pregnancy; includes pregnancy 
induced hypertension and preeclampsia/eclampsia 
HR Hazard ratio 
ICD 9, ICD 10 International Statistical Classification of Diseases and Related 
Health Problems-ninth and tenth revision 
ICMART The International Committee Monitoring Assisted Reproductive 
Technologies 
ICSI Intracytoplasmic sperm injection; a technique to fertilize an 
oocyte by injecting one single sperm directly in the oocyte 
Infant mortality Death of child within the first year of life 
IQR Interquartile range 
IVF In vitro fertilization 
LBW Low birth weight, <2500 grams, VLBW very low birth weight, 
<1500 grams 
LGA Large for gestational age (more than two standard deviations 
above Swedish growth standard) 
MBR Medical Birth Register 
Monozygotic 
twinning 




Death of a live-born child within the first 28 days of life. Early 
neonatal mortality, death of live-born child within the first 7 
days of life. Late neonatal mortality, death of live-born child 
covering the time after the first seven days of life until 28 days 
NGS Next generation sequencing 
NPR National Patient Register 
OHSS Ovarian hyperstimulation syndrome 
OR Odds ratio 
PCOS Polycystic ovarian failure syndrome; a hormonal disorder 
causing infrequent, irregular or prolonged menstrual periods, 
usually accompanied with high levels of androgens (male 
hormones). Numerous small follicles are developed but often 
fail to ovulate regularly 
PCR Polymerase chain reaction 
Perinatal 
mortality 
Stillbirths and deaths in the first week of life 
PGD Preimplantation genetic diagnosis 
PGS Preimplantation genetic screening 
PGT Preimplantation genetic testing; preimplantation genetic testing 
for monogenic disorders (PGT-M), preimplantation genetic 
 
testing for structural rearrangements (PGT-SR), preimplantation 
genetic testing for aneuploidy (PGT-A) 
PIN Personal identification number 
Placenta previa Low-lying placenta or a placenta that partially or completely 
covers the inner part of cervix 
Placental 
abruption 
When placenta partially or completely separates from the uterine 
wall 
PPH Postpartum hemorrhage, >1000mL in Sweden 
Preeclampsia High blood pressure (≥ 140/90) with significant amounts of 
protein in the urine (≥0,3g in a 24-hour urine specimen or a 
protein/creatinin ratio ≥0,3mg/dL) in a pregnant woman after 20 
weeks of gestation. ICD 10 code O14-O15. According to new 
definitions, proteinuria is no longer considered necessary for PE 




High blood pressure (≥140/90) without significant amounts of 
protein in the urine (≥0,3g in a 24-hour urine specimen or a 
protein/creatinin ratio ≥0,3mg/dL) in a pregnant woman after 20 
weeks of gestation. ICD 10 code O13 
Q-IVF The National Registry of Assisted Reproduction 
RCT Randomized controlled trial 
RNA Ribonucleic acid 
RR Risk ratio (or relative risk)   
SART Society for Assisted Reproductive Technology 
SC Spontaneous conception 
SCB Statistics Sweden 
SD Standard deviation 
SET Single embryo transfer 
SGA Small for gestational age (more than two standard deviations 
below Swedish growth standard) 
SNQ Swedish Neonatal Quality Register 
Stillbirth Intrauterine fetal death ≥ 22 weeks of gestation from July 1, 
2008 (≥28 weeks of gestation before July 1, 2008) 
WHO World Health Organization 
 






1.1 Infertility - an overview 
The use of assisted reproductive technology (ART) has increased rapidly since the 
birth of the first child following in vitro fertilization (IVF) in 1978 (Steptoe and 
Edwards, 1978) and today approximately 8 million children have been born 
following ART (Adamson et al., 2019). ART involves all treatment where human 
gametes are handled outside the body to achieve a pregnancy. IVF, intracytoplasmic 
sperm injection (ICSI) as well as oocyte donation are all such treatments whereas 
artificial insemination with husbands or donated sperm is not (Zegers-Hochschild et 
al., 2017). Medically assisted reproduction (MAR) is a wider term including ART 
but also ovulation induction, ovulation triggering, insemination and uterine 
transplantation. In total, 10-15% of heterosexual couples suffer from infertility 
defined by the World Health Organization (WHO) as "failure to achieve a clinical 
pregnancy after 12 months or more of regular unprotected sexual intercourse without 
any other reason, such as breastfeeding or postpartum amenorrhea". According to 
WHO, infertility is a public health problem and the United Nations has included 
infertility and its treatment as part of Sexual and Reproductive Human Rights. 
Regarding the increasing demand on ART treatment it is of utmost importance to 
offer women/couples suffering from infertility safe and effective treatment.  
 
There are several reasons behind infertility. Around 1/3 are attributable to female 
factors, 1/3 to male factors and 1/3 a combination of both female and male factors or 
unknown factors. Infertility rates have increased in the last century, mainly due to 
problems associated with increasing maternal age and postponing childbearing 
(Schmidt et al., 2012). The women´s age is the most important predictive factor for 
the chance of a live birth, depending on decreased ovarian reserve and also an 
increase in chromosomal abnormalities, resulting in failed implantation and/or 
increased miscarriage rate. Accordingly, the chance of a live birth following ART 
decreases with increased maternal age with a 26% chance of live birth per initiated 
fresh cycle for women aged 30-35 but only 8% for women aged ≥42 years. Per 
embryo transfer, the live birth rate in fresh cycles is substantially higher, 35% for 
women aged 30-35 years and 11% for women aged ≥42 years (www.qivf.se). Access 
to and financing of infertility treatment varies globally, as does the percentages of 
ART children in the national birth cohorts. In Sweden, infertility treatment is offered 
both in public and private care, in 6 and 13 centers, respectively. The first ART child 
 





in Scandinavia was born 1982 in Gothenburg. Following 18,639 treatment cycles 
with autologous gametes, 5137 children were born in 2017, comprising 4.3% of the 
total national birth cohort in Sweden. Additionally, 350 children were born following 




Figure 1. Number of ART children per year in Sweden 1982-2017 (www.qivf.se) 
 
 
1.2 Legal aspects on ART in Sweden 
In Sweden, insemination with donated sperm is regulated since 1985 (1984:1140) 
and ART since 1988 (1988:711). Today, ART is regulated by The Genetic Integrity 
Act (2006:351). Other acts and regulations such as the Bio banks in Medical Care 
Act, however, have an impact on the regulations. In addition, as a member of the 
European Union, Sweden is obliged to comply with the European Tissues and Cells 
Directive (2004/23/EC). This directive applies to the donation, testing, preservation, 
storage and distribution of human tissues and cells intended for human use and 
includes gametes used in ART.  
 
Embryos can be frozen up to ten years following new regulations in Sweden in 2019. 
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Infertility treatment with donor oocytes/sperm has previously only been performed 
at University Hospitals but following January 1, 2019 private clinics can get 
permission for donation treatment. Both known and anonymous donors are allowed 
in Sweden. Information regarding the anonymous donors is stored for 70 years, 
however, the donor is anonymous to the parents. The child has the right to know its 
genetic origin and parents undergoing infertility treatment with donated 
oocytes/sperm are thus highly recommended to tell the child its origin. The child 
conceived by donated oocytes or sperm has the right to access this data when the 




Table 1. Regulations for different ART treatments in Sweden 
PGT-M 
PGT-SR 
Allowed since 1994 for monogenic diseases, chromosomal 
aberrations or sex-linked disorders. 
PGT-HLA Allowed in specific cases following permission from the 
National Board of Health and Welfare. 
PGT-A Only allowed in research following ethical approval. 
Oocyte donation Allowed since 2003 
IVF/ICSI with donated sperm Allowed since 2003 
AID and IVF/ICSI in female same-
sex couples 
Allowed since 2005 
IVF/ICSI in single women Allowed since 2016 
Use of donated oocytes + donated 
sperm in the same treatment cycle, 
embryo donation 
Allowed since 2019. The National Board of Health and Welfare 
is working on guidelines and the combination of sperm and 
oocyte donation is not practiced yet, neither is embryo donation.   
Surrogacy Not allowed 
 
PGT-M preimplantation genetic testing for monogenic disorders, PGT-SR preimplantation genetic 
testing for structural rearrangements, HLA human leukocyte antigen, PGT-A preimplantation 
genetic testing for aneuploidy, IVF in vitro fertilization, ICSI  intracytoplasmic sperm injection, 










1.3 The IVF and ICSI procedure 
IVF is a series of procedures enabling fertilization of an oocyte with sperm outside 
the body (in vitro). In controlled ovarian hyperstimulation, follicle stimulating 
hormone (FSH) or human menopause gonadotropin (hMG) is given to enable 
development of multiple follicles. In parallel, a gonadotropin releasing hormone 
(GnRH) agonist or antagonist is given to inhibit premature luteinization. The 
development of the follicles is monitored through vaginal ultrasound and/or serum 
estradiol levels. To enable the final oocyte maturation, human chorionic 
gonadotropin (hCG) is given as a single dose. In the next step, approximately 36 
hours after the administration of hCG, ovum pick up is performed transvaginally with 
guidance of transvaginal ultrasound in local anesthesia combined with analgesics and 
sometimes light sedation. Following the ovum pick up the oocytes are fertilized with 
sperm on specific dishes and then cultured between 2 and 5-6 days. In Sweden, in 
around 50% of cycles, mainly due to e.g. low sperm count or low sperm motility, a 
more invasive technique called ICSI, where a single sperm is injected into the oocyte, 
is used. In the last step of IVF, the embryo is transferred to the uterine cavity either 
at culture day 2 to 3 or 5 and surplus good quality embryos are cryopreserved.  
 
During the 90s and in the beginning of this century, many countries reported on 
multiple birth rates of 20-30% following IVF treatment. In a large Swedish 
population-based study, published in Lancet 1999, the multiple birth rate was 27% 
in the IVF group compared to 1% in the background population (Bergh et al., 1999). 
The same study, including 5856 children after ART showed a 5-folded increase in 
preterm birth (PTB, <37 weeks) and low birth weight (LBW, <2500 grams) in the 
ART cohort, mainly explained by the higher rate of multiples. When comparing only 
singletons, a 2-3 folded increase in adverse outcome was noted. Later, several meta-
analyses have confirmed adverse outcomes in regards of PTB and LBW also in 
singletons born following ART as summarized in Table 2 (Helmerhorst et al., 2004, 
Jackson et al., 2004, McDonald et al., 2009, Pandey et al., 2012, Qin et al., 2017).  
 
Single embryo transfer (SET) is the most effective way of reducing multiple births 
and the associated adverse outcomes. A Finnish study was the first study to 
demonstrate SET as a successful option in IVF (Vilska et al., 1999). In 2004 a large 
randomized control trial (RCT) including 661 women <36 years compared live birth 
rate in women with at least two good-quality embryos. The women were randomized 
either to transfer of a single fresh embryo and a subsequent transfer of a single frozen 
embryo if there was no live birth, or to undergo a single transfer of two fresh 
 





embryos. The results showed a dramatic reduction in the rate of multiple births 
following SET (33% in double embryo transfer, 1% in SET) without substantially 
reducing the live birth rate (Thurin et al., 2004). In Sweden, SET is highly 
recommended by the National Board of Health and Welfare and the numbers of 
cycles with SET are amongst the highest in Europe (Figure 2). Worldwide, the use 
of SET has also gained in popularity, though, the latest numbers from Europe still 
show a multiple birth rate of 17% in fresh cycles and 12% in frozen cycles in 2015 
(De Geyter et al., 2020) whereas the latest report from the United States reveals a 





















The use of ICSI varies in different countries. In Sweden around 50% of all ART 
cycles are ICSI cycles while European data shows a predominance of ICSI, 71.3 % 
ICSI versus 28.7% IVF (De Geyter et al., 2020). In the beginning, following the birth 
of the first ICSI baby in 1992 (Palermo et al., 1992), ICSI was used only for severe 
male infertility but today ICSI is also used for mild male infertility and in cases of 
mixed or unexplained infertility. 
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1.4  Advanced techniques 
Blastocyst transfer 
An embryo is considered a blastocyst when it reaches the 64-cell stage which occurs 
at day 5-6 post fertilization. Blastocyst transfer, i.e. transferring the embryo into the 
uterine cavity on day 5 or 6 is, compared to transferring the embryo at the cleavage 
stage (i.e. day 2-3 at the 4 - or 8-cell stage), considered more physiological since 
embryos at an earlier developmental stage are usually located in the fallopian tube. 
In spontaneous conception (SC), the embryo reaches the uterine cavity around day 
4-5 post fertilization (morula or blastocyst stage). The embryo can be 
morphologically graded at day 2 at the earliest, hence allowing selection and transfer 
of good quality embryos from that day.  
 
In the early days of IVF, transfer of cleavage stage embryos was the standard since 
studies during the 80s showed that few embryos survived culturing in vitro until the 
blastocyst stage (Bolton et al., 1989). In the late 90s stage-specific culture medias 
were developed and the embryos developing in vitro were transferred from one 
media to another at day 2 or 3, increasing both the development from a cleavage 
stage embryo to a blastocyst and the implantation/pregnancy rate (Gardner et al., 
1998a, Gardner et al., 1998b). The advantage with blastocyst transfer is the 
possibility to choose the most viable embryos for transfer whereas the major 
disadvantage is having no embryos developing to this stage and thus no embryos 
available for transfer.  
 
The first pregnancies and live births following transfer of human blastocysts were 
reported in 1991 (Bolton et al., 1991). Following the introduction of a new freezing 
technique, vitrification, described more closely on pages 24-25, survival and 
implantation rates for frozen blastocysts improved significantly (Stehlik et al., 2005) 
and hence, blastocyst transfer is today clinical routine in many countries. In 2017, 
more than 30% of fresh cycles and almost 90% of frozen cycles were performed as 
blastocyst transfer in Sweden (Figure 3) (www.q-ivf.se). A Cochrane review 
reported that blastocyst transfer, in comparison to cleavage stage transfer, is 
associated with increased delivery rates in fresh cycles (adjusted odds ratio [AOR] 
1.48, 95% confidence interval [CI] 1.20-1.82). The review also suggested that if 29% 
of women deliver a live birth following a cleavage stage transfer in a fresh cycle, 
then around 40% would do so following a fresh blastocyst transfer. Yet, even though 
there is a difference for fresh transfers, the cumulative live birth rate when including 
 





both fresh and frozen cycles from the same oocyte pick up, was not significantly 













Figure 3. Distribution of day 2-3 and day 5-6 embryos in Sweden  
in 2017 for fresh and frozen transfers (www.q-ivf.se)  
 
 
Frozen embryo transfer 
Since the early 80s, when the first baby was born following frozen embryo transfer 
(FET) (Trounson and Mohr, 1983, Zeilmaker et al., 1984) the technique has 
improved and success rates increased, and FET is today more widely used. A major 
contribution to this development is SET, leaving a number of supernumerary 
embryos available for freezing. Recently, the freeze-all technique has been 
introduced which reduces the risk of ovarian hyperstimulation syndrome (OHSS), a 
potentially life-threatening complication for the woman. 
 
In Europe, the rate of FET has steadily been rising and in 2015, cryopreservation 
constituted 25.7% of all cycles with the highest rate in Switzerland being 45% (De 
Geyter et al., 2020). In the United States the rate of FET have been doubled since 
2015, being almost 70% of the non-donor ART in 2017 (www.cdc.gov/art). The 
latest Swedish report from 2017, reported FET in 6718 out of a total of 15,294 
embryo transfers with autologous gametes, i.e. in 44% of all cycles (www.q-ivf.se).  
 
Even though fresh embryo transfer is still the norm in many countries, FET including 
the freeze-all strategy has emerged as an alternative and previous studies have shown 
better perinatal outcome in terms of lower rates of PTB, LBW and small for 
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et al., 2013, Maheshwari et al., 2018, Zhang et al., 2018). It has been suggested that 
the supra-physiological environment in the uterus and the endometrium, caused by 
controlled ovarian hyperstimulation, is a possible reason for the poorer perinatal 
outcome in singletons born following fresh embryo transfer in comparison to FET 
and elevated estrogen levels have been shown to be associated with a higher risk of 
















Figure 4. Distribution of embryo transfers following different techniques in  




Four large RCTs have investigated the differences in live birth rate following fresh 
and FET in freeze-all cycles. The first study investigated live birth rate in 1508 
women with polycystic ovary syndrome (PCOS) randomized to either a fresh transfer 
or cryopreservation of all embryos with a subsequent frozen transfer. The results 
showed a higher live birth rate following frozen transfer with a relative risk (RR) of 
1.17 (95% CI 1.05-1.31) (Chen and Legro, 2016). Later studies by Shi et al. and 
Vuong et al. investigated live birth rate in 2157 and 782 ovulatory women, 
respectively, randomized to a fresh or frozen transfer. These studies showed no 
differences with a RR of 0.97 (95% CI 0.89-1.06) and 1.07 (95% CI 0.88-1.31), 
respectively (Shi et al., 2018, Vuong et al., 2018). In a systematic review and meta-
analysis, published last year, it was concluded that there is currently no overall 
support for a higher live birth rate following FET in comparison to fresh transfer in 
the overall IVF/ICSI population. However, in a subgroup analysis, a higher live birth 
rate was seen in hyper-responders, but not in normo-responders (Roque et al., 2019). 
 





The latest RCT on live birth rate, published in Lancet 2019, showed a significantly 
higher live birth rate following frozen transfer in comparison to fresh transfer (RR 
1.26, 95% CI 1.14-1.41) in 825 ovulatory women (Wei et al., 2019). Moreover, in 
an RCT, there was no difference in ongoing pregnancy rate in 460 normo-ovulatory 
women following the first single blastocyst transfer in a freeze-all cycle compared to 
a fresh embryo transfer (Stormlund et al., 2019). The reasons for the differences in 
live birth rate between the studies are not completely known. However, the included 
women differ in regards of ovulatory function. Further, the study by Wei et al. 
included only blastocysts while the others included only cleavage stage embryos. 
Additionally, a maximum of two embryos were transferred in the first three studies, 
while in the study by Wei et al. only SET was conducted.  
 
Different cycle regimens used in FET 
FET can be performed in either a natural, a stimulated or a programmed cycle. In a 
natural cycle the woman’s endogenous menstrual cycle is used without exposure to 
exogenous hormones leading to a natural folliculogenesis and ovulation. The 
stimulated cycle in FET differs from the one in fresh cycles where the stimulation is 
aimed at producing large number of oocytes. In FET, the stimulation is rather aimed 
at ovulation induction and subsequently preparing the lining of the uterine cavity for 
embryo implantation. The primary approach in Sweden for stimulated FET is 
aromatase inhibitors while gonadotropins are only given in exceptional cases. An 
alternative, the programmed cycle, means preparing the endometrium for 
implantation by giving estrogen and progesterone and sometimes adding a GnRH 
agonist/antagonist to suppress natural ovulation. A Cochrane review, including 18 
RCTs, comparing different cycle regimens in FET in a total of 3815 women did not 
find evidence for supporting one treatment modality in preference for another when 
investigating live birth rate, however, with low quality of evidence (Ghobara et al., 
2017). In the review, natural cycles including modified natural cycles were compared 
to programmed cycles with and without GnRH suppression but also subtypes of 
ovulation induction with hMG alone and clomiphene+hMG were compared.  
 
Recently, an interest has raised concerning the role of corpus luteum (CL) in frozen 
cycles. Four studies have evaluated the risks for altered vascular adaptation 
associated with pregnancies following FET according to the presence or absence of 
CL. CL is known to produce estrogen and progesterone, but also relaxin, a hormone 
that can regulate the maternal cardiovascular and renal systems and hence mediates 
the hemodynamic changes occurring during pregnancy. A study on 184 women 
revealed undetectable serum relaxin concentrations in women where no CL was 
 





present (von Versen-Hoynck et al., 2019). Furthermore, two smaller studies showed 
that the drop in mean arterial pressure was lacking in women with 0 or >3 CL and 
that the perturbations in blood pressure remained in the third trimester (von Versen-
Hoynck et al., 2019, von Versen-Hoynck et al., 2020). Finally, in a prospective 
cohort study on almost 700 women, programmed cycles in FET with no CL were 
associated with an almost 3-folded risk of preeclampsia compared to modified 
natural cycles with one CL (von Versen-Hoynck et al., 2019).  
 
In programmed cycles the ovaries are not stimulated, no CL is present and hence 
luteal phase support is given in early pregnancy. In addition to these cycles, modified 
natural cycles can be performed by using hCG as ovulation trigger for controlling 
the timing of ovulation in an otherwise natural cycle. In natural cycles including the 
modified natural cycle, the cycle is associated with physiological estradiol levels in 
the presence of one CL and in stimulated FET at least one CL is present. In a 
programmed cycle the pituitary-ovarian hormonal axis is suppressed by exogenous 
estradiol leading to the absence of a CL.  
 
Different freezing techniques 
Various protocols for freezing have been introduced, differing particularly in type 
and concentration of cryoprotectant, cooling rates and type of device used. Today, 
two freezing techniques are available in the IVF laboratory. In the older one, used 
for more than 20 years and called slow-freezing, the embryo is frozen slowly at a 
decrease of approximately 1° Celsius (C) per minute and then stored in liquid 
nitrogen at a temperature of -196°C. The idea of the technique is to permit cellular 
dehydration while minimizing intracellular ice formation (Lassalle et al., 1985, 
Testart et al., 1986). Over the last decade, there has been a shift from conventional 
slow-freezing towards vitrification of human embryos, a cryopreservation method 
which turns the embryo into a glass-like state without formation of ice (Mukaida et 
al., 1998, Kuwayama et al., 2005). Vitrification is considered as an ultra-rapid 
freezing method, 600 times faster than slow-freezing, and minimizing the time the 
embryo is exposed to the most harmful temperatures between +15°C and -5°C.  
 
Compared to slow-freezing, vitrification has resulted in improved embryo survival 
rates and improved clinical pregnancy/live birth rates (Balaban et al., 2008, Fasano 
et al., 2014, Levron et al., 2014, Li et al., 2014, Debrock et al., 2015, Rienzi et al., 
2017). Today, the majority of embryos transferred in frozen cycles are vitrified 
blastocysts since the combination of blastocysts and vitrification have turned out to 
be more successful than blastocysts and slow-freezing (Stehlik et al., 2005). If 
 









Preimplantation genetic testing  
More than 10,000 children have been born following preimplantation genetic testing 
(PGT) for monogenic disorders (PGT-M), structural rearrangements (PGT-SR) and 
aneuploidy (PGT-A) (De Rycke et al., 2017) since the birth of the first PGT child in 
1990 (Handyside et al., 1990). The technique has recently been re-named. Previously 
the terms preimplantation genetic diagnosis (PGD) and preimplantation genetic 
screening (PGS) were used. Nowadays, PGD has been re-named into PGT-M and 
PGT-SR and PGS re-named into PGT-A, the name now also containing the 
indication for the procedure. The terms PGD and PGS have been used for over 25 
years and are also the terms that are referred to in the Swedish law.   
 
Couples carrying or suffering from monogenic diseases, inherited chromosomal 
aberrations or X-linked disorders can be offered PGT-M/PGT-SR to limit the risk of 
the child inheriting the disorder. Regarding X-linked disorders the defect gene is 
located on the X-chromosome and the X-linked disorders are thus categorized under 
PGT-M. Couples undergoing PGT- M and PGT-SR are usually not suffering from 
sub fertility. PGT-A, the parallel technique, is used to screen for aneuploid embryos 
in presumed genetically and chromosomally normal couples. In women of advanced 
age, the higher rate of implantation failure and recurrent pregnancy loss is thought to 
be due to a higher proportion of aneuploid embryos. The technique aims at excluding 
embryos with aneuploidy, hence increasing the chance of a live birth. Today, there 
is, however, conflicting results whether PGT-A improves pregnancy and live birth 
rates or not. The first large RCT on 408 women randomized to IVF with or without 
PGT-A showed a reduction in live birth rate following IVF with PGT-A in women 
35-41 years of age (Mastenbroek et al., 2007). In a meta-analysis, including nine 
RCTs on IVF with PGT-A and IVF without PGT-A in mainly cleavage stage 
embryos, no difference in live birth rate could be found (Mastenbroek et al., 2011). 
In a later RCT on 396 women, PGT-A did not affect live birth rate in comparison to 
ICSI without PGT-A (RR 1.07, 95% CI 0.75-1.51) (Verpoest et al., 2018). The latest, 
and largest, RCT on almost 700 women did not observe any differences in ongoing 
pregnancy rate at 20 weeks of gestation in women randomized to a PGT-A cycle 
versus a non-PGT-A cycle in blastocysts (p=0.32) (Munné et al., 2019). However, 
several observational studies, summarized in a systematic review (Lee et al., 2015) 
 





show improved implantation and pregnancy rates. Owing to the lack of evidence, 
PGT-A is not allowed in Sweden in clinical practice.  
 
To enable PGT, fertilization is performed either with IVF or ICSI. Usually ICSI is 
used for fertilization, avoiding contamination of the oocyte’s zona pellucida with 
extraneous sperms leading to possibly false results. In the latest European report on 
PGT, ICSI was used in 91% of cycles (De Rycke et al., 2017). Following 
fertilization, one or two, or up to ten, cells are removed from the embryo at day 3 or 
day 5-6 and analyzed for the specific disorder using fluorescence in situ hybridization 
(FISH), polymerase chain reaction (PCR)-based techniques, array-comparative 
genome hybridization (CGH) or next generation sequencing (NGS). PCR is most 
commonly used for monogenic disorders while FISH, array-CGH and NGS are used 
in the majority of cases with chromosomal aberrations and sex-linked disorders.  
 
Every human, animal, plant, bacteria or virus contains genetic material such as 
deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequences that are unique 
to their species and to the individual member of that species. PCR is a method used 
to amplify, i.e. make many identical copies, of these unique sequences, sequences 
that can then be analyzed and compared to sequences in a person not carrying the 
specific disease, enabling transfer of an unaffected embryo.  
 
FISH is applied to detect genetic abnormalities including the presence of an abnormal 
number of chromosomes in a cell or loss of a chromosomal region or a whole 
chromosome. A fluorescent copy (probe) of the DNA sequence of interest is 
produced. Following denaturation of the DNA in both the probe and the target, by 
either high temperature or chemicals, the probe and target sequences are then mixed 
together. The probe specifically hybridizes to its complementary sequence on the 
chromosome (the abnormal part) and it will be possible to detect the site of 
hybridization directly and hence sort out the affected embryo/embryos. 
 
In array-CGH even small deletions or duplications in the genome can be detected. 
However, CGH is only able to detect unbalanced chromosomal abnormalities. 
Balanced chromosomal abnormalities, such as reciprocal translocations and 
inversions, do not affect copy number which is what is detected by CGH. NGS is a 
relatively novel method for DNA sequencing and all NGS platforms are able to 
sequence millions of small fragments of DNA in parallel. NGS can be used to 
sequence entire genomes or a small number of individual genes. NGS is, in parallel 
to CGH, used for detection of deletions and duplications. In accordance to array-
 





CGH, NGS is not able to separate normal chromosomes from balanced 
abnormalities.   
     
Following the genetic analysis, an unaffected embryo, or in some cases two, is 
transferred to the uterine cavity. The rate of transferable embryos varies with 
indication for PGT with the lowest rate, 19%, in reciprocal translocations (De Rycke 
et al., 2017). PGT-M and PGT-SR are today considered as a good alternative to 
invasive prenatal tests, including chorionic villus sampling and amniocentesis, 
performed during first and early second trimester and more psychologically 
acceptable for many couples than termination of pregnancy. PGT-M and PGT-SR 
offers the couples an alternative to donation treatment or adoption. However, the 
disadvantage of PGT is the need of IVF/ICSI, a treatment with associated risks but 
also costs. In addition, a delivery/live birth rate per aspiration around 20% is rather 
low taken into account that these couples are not suffering from sub fertility. In 
general, the risk for a misdiagnosis, i.e. transferring an affected embryo, is limited. 
According to the annual report from the European Society of Human Reproduction 
and Embryology (ESHRE) PGT Consortium, no misdiagnoses for the latest dataset 
on 2066 live born were reported and a decline in the rate of misdiagnosis has been 
seen over the years (De Rycke et al., 2017). Whether the decline is a true decline 
following better laboratory quality or an effect of unwillingness to report 
misdiagnosis is unknown. In the early days of PGT in Sweden, a confirmative 
amniocentesis was recommended. Considering the accuracy of the new techniques 
used for genetic analysis (Harton et al., 2011), no such confirmation is recommended 
any longer, except for in exceptional cases. To date, no misdiagnosis have been 
reported in Sweden (personal communication, Charles Hanson and Elisabeth Syk 
Lundberg, PGT offering clinics in Sweden).  
 
The first child following PGT in Sweden was born in 1997 in Gothenburg and today 
more than 300 children have been born in Sweden following the technique. PGT-M 
and PGT-SR are currently performed at two centers, at university hospitals in 
Gothenburg and Stockholm. For the first couple of years following 1994, PGT was 
only allowed in cases with "severe genetic diseases leading to death in early 
childhood". Today PGT is regulated in the Genetic Integrity Act (2006:351) and 
allowed for monogenic diseases, inherited chromosomal aberrations and X-linked 
and gender-dependent disorders. 
 
Delivery rates per oocyte aspiration are comparable for PGT and IVF/ICSI 
pregnancies, being around 20% (De Rycke et al., 2017, De Geyter et al., 2020).  
 






Several national and international surveillance systems regarding ART have been 
established.  
 
Following the birth of the first IVF child in Sweden, data on ART treatments has 
been collected. During 1982-2006 aggregated data were collected by the National 
Board of Health and Welfare annually. In addition, at four occasions during these 
years, data for all ART cycles resulting in a delivery, were collected for research 
purpose. These data include full maternal identity and are stored at the Medical Birth 
Registry (MBR), thus named MBR-IVF in this thesis. In 2007, the Swedish National 
Quality Register of Assisted Reproduction (Q-IVF) was founded (www.q-ivf.se). 
The Q-IVF collects information from all IVF clinics with full parental identification 
and enables follow-up on treatment efficacy and safety for the children as well as the 
mothers. The register is primarily a base for developmental and quality work but can 
also be used for research. The coverage rate is close to 100%. Q-IVF is presented 
more thoroughly in the Methods section.  
 
ESHRE was founded in 1985 by Sir Robert Edwards, the Nobel Prize winner in 2010 
for the development of IVF. ESHRE has the main aim to promote interest in, and 
understanding of human reproduction and embryology (ESHRE). ESHRE also 
promotes research in the field and enhance safety and quality in ART. The European 
IVF Monitoring (EIM) Consortium, introduced in 1999, collects data from the 
national IVF registries (EIM). The IVF Consortium was established to collect 
national data for Europe including complications such as OHSS and to a smaller 
extent also follow-up children's well-being and moreover, report on the availability 
and the structure of services in the different countries. Data are published in annual 
reports and covers approximately 84% of European countries active in ART. The 
latest report published in 2020 contains data for 2015 (De Geyter et al., 2020). Since 
1999, the PGT Consortium of ESHRE collects data on the accuracy, reliability, 
effectiveness and safety of PGT and the 14th report was published in 2017 (De Rycke 
et al., 2017). In addition, the Consortium establishes guidelines.  
 
The International Committee Monitoring Assisted Reproductive Technologies 
(ICMART) is an independent, international organization covering 63-70% of the 
world’s ART activity with data on almost 2 million ART cycles and 350,000 
deliveries in 2015. However, many countries are still missing in the numbers, 
especially in the Middle East and Asia. ICMART provides data on availability, 
 





effectiveness and safety regarding ART. The first ICMART World Report was 
published in 1989 and the latest annual report in 2018 cover data for 2011 (Adamson 
et al., 2018).  
 
Centers for Disease Control and Prevention (CDC) is a public health institute in the 
United States responsible for control and prevention of diseases, including infertility, 
with annual reports published on efficacy and safety in ART (www.cdc.gov/art). The 
Society for Assisted Reproductive Technology (SART), founded in 1985, includes 
>90% of all ART clinics in the United States and reports on birth outcome data from 
all member clinics in annual reports and also sets national guidelines for best practice 
in ART. The data collected by SART is also included in the annual reports from the 
CDC.  
 
In summary, the main aim for the national and international registries is to follow 
treatment success as well as medical risks for the children conceived through ART 
and the mothers undergoing ART. However, individual linkage is usually not 
possible. In the Nordic countries all citizens are given a unique personal 
identification number (PIN) either at birth or at immigration. The PIN is used by 
authorities, health care, schools and universities (both public and private). PIN is the 
unique identifier and the key variable when linking health- and quality registers and 
enables large scale register-based studies involving several registers. 
 
 
1.6 Neonatal outcome after ART 
Besides efficacy data, i.e. pregnancy- and live birth rates, it is of utmost importance 
to study the safety of the children and their mothers in connection to the different 
procedures introduced in ART. 
 
 
IVF/ICSI versus SC 
Neonatal outcomes following IVF/ICSI have been extensively analyzed. The reason 
for the increased risk of adverse neonatal outcome in ART has mainly been 
associated with the higher rates of multiple births in ART as discussed in chapter 1.3. 
However, several meta-analyses and large cohort studies consistently show 
compromised outcomes also for singleton pregnancies following ART in comparison 
to SC, even after adjustment for relevant confounders. The latest meta-analysis, 
including 52 cohort studies with a total of 180,000 IVF/ICSI singletons and 4.6 
 





million SC singletons born worldwide, showed increased risks for particularly very 
PTB (VPTB) and very LBW (VLBW) (Qin et al., 2017). Several previous meta-
analysis (Helmerhorst et al., 2004, Jackson et al., 2004, McDonald et al., 2009, 
Pandey et al., 2012) are consistent with the study by Qin et al. The AORs or RRs for 
these meta-analyses are summarized in Table 2.  
 
Regarding birth defects, several studies including systematic reviews and meta-
analyses indicate a 30-40% higher risk for birth defects following ART as opposed 
to SC, in the study by Pandey et al. as much as a 70% increase (Pandey et al., 2012, 
Hansen et al., 2013, Qin et al., 2017, Zhao et al., 2020). A summary on these meta-
analyses is presented in Table 3.  
 
A large Nordic cohort study including 61,281 ART singletons and 350,811 
spontaneous singletons reported major birth defects in 3.4% of ART singletons vs. 
2.9% in SC singletons with an AOR 1.14 (1.08-1.20). For specific organ systems, 
significantly increased risks were found in the nervous system, the eye, ear, face and 
neck, the heart, the gastrointestinal and urinary systems as well as in the musculo-
skeletal system (Henningsen et al., 2018). For cardiac defects, an increased risk 
following IVF/ICSI has also been summarized in a systematic review and meta-
analysis (Giorgione et al., 2018). In an earlier Swedish study (n=15,570), the risks 
of certain specific birth defects, such as neural tube and cardiovascular defects and 










Table 2. A summary on adverse perinatal outcome in singletons.  
Systematic reviews and meta-analyses         
Author 











ART vs SC Adjusted 
for at least maternal 
age 
RR, 95% CI OR, 95% CI RR, 95% CI RR, 95% CI ART vs SC, % 
No of studies 



















10.9 vs 6.4 
VPTB <32 weeks 3.3           
(2.0-5.3) 
3.1        
(2.0-4.8) 




2.4 vs 1.2 
LBW <2500 grams 1.7           
(1.5-1.9) 
1.8            
(1.4-2.2) 




8.7 vs 5.8 








2.0 vs 1.0 








7.1 vs 5.7 






1.1 vs 0.6 
ART assisted reproductive technology, SC spontaneous conception, RR relative risk,  
CI confidence interval, OR odds ratio, PTB preterm birth <37 weeks, VPTB very preterm birth 
<32 weeks, LBW low birth weight <2500 grams, VLBW very low birth weight <1500 grams,    
SGA small for gestational age 
 
Considering the increased use of ICSI worldwide it is of interest to study whether 
this technique poses higher perinatal risks compared to IVF. In ICSI, the natural 
selection of sperm is by-passed. Moreover, the sperm injection could potentially 
harm the oocyte and contamination of the oocyte´s cytoplasm with culture media 
might occur following the sperm insertion. These mechanisms have led to a concern 
regarding the perinatal outcomes. Reassuringly, studies have shown comparable or 
even slightly better, perinatal outcomes following ICSI compared to IVF. In a 
systematic review and meta-analysis including five studies for PTB, a significantly 
lower risk for PTB following ICSI in comparison to IVF in singleton pregnancies 
was found (AOR 0.80, 95% CI 0.69-0.93) (Pinborg et al., 2013). Regarding birth 
defects, most studies found no differences between IVF and ICSI children (Wen et 
al., 2012, Zhu et al., 2019). However, in one meta-analysis, a higher risk of 
genitourinary malformations following ICSI was found. Yet, when including only 
high qualitative studies the difference disappeared (Massaro et al., 2015).  
 
 





Table 3. A summary on birth defects in singletons.  












ART assisted reproductive technology, SC spontaneous conception,  
RR relative risk, CI confidence interval  
 
Frozen embryo transfer versus fresh embryo transfer 
Singletons born after FET have better perinatal outcomes than singletons born 
following fresh embryo transfer regarding PTB, LBW and SGA (Wennerholm et al., 
2013, Maheshwari et al., 2018, Zhang et al., 2018). However, several studies have 
reported on a higher risk of being born as large for gestational age (LGA) and 
macrosomic (≥4500 grams) following FET both compared to fresh transfer and to 
SC (Wennerholm et al., 2013, Pinborg et al., 2014). In two meta-analyses (Berntsen 
and Pinborg, 2018, Maheshwari et al., 2018) a 1.5-folded risk for LGA and an almost 
two-folded risk for macrosomia was seen when comparing FET to fresh transfer. In 
a large “freeze-all” RCT on PCOS women, an almost 1,5-folded risk was seen for 
both LGA and macrosomia following FET in comparison to fresh transfer (Zhang et 
al., 2018). Moreover, FET seems to be associated with higher rates of post term birth 
(Wennerholm et al., 2013). No differences in the incidence of birth defects have been 
demonstrated when comparing fresh and frozen transfer (Pelkonen et al., 2014, 
Maheshwari et al., 2018).  
 
The current evidence is not indicating any major differences in perinatal outcome 
using different freezing techniques. A Finnish study comparing 276 children, both 
singletons and multiples, born from vitrified and slow-frozen day 2-3 embryos did 
not show any significant differences in rate of PTB (Kaartinen et al., 2016). Neither 
did a study on 4721 singletons from vitrified blastocysts and 1965 singletons from 
slow-frozen blastocysts reveal any differences in perinatal outcome (Li et al., 2014). 
The latest study, comparing 297 pairs of newborns from vitrified and slow-frozen 
Author 









ART vs SC               RR,     
95% CI                        
RR,     
95% CI                     
ART vs 
SC, %
RR,        
95% CI                        
No of studies                 
No of ART 
singletons         
7                     
4382 
23                  
48,944 
29               
77,630 
46                
112,913 
Birth defects 1.7      
(1.3-2.1) 
Any       
1.4            
(1.3-1.4) 
Major       




1.4        
(1.3-1.5) 
 





day 3 embryos, showed similar results (Gu et al., 2019).  
 
Blastocyst transfer versus cleavage stage transfer 
Extended culturing to the blastocyst stage has been found to be associated with a 
slightly increased risk for PTB compared to cleavage stage transfer. Three meta-
analyses have shown an increased risk for PTB and VPTB (<32 weeks) (Table 4) 
(Dar et al., 2014, Martins et al., 2016, Alviggi et al., 2018). Studies also indicate that 
extended culture is associated with increased birth weight (Makinen et al., 2013, Zhu 
et al., 2014). A Swedish register-based study was the first larger study (n=1311) 
reporting on neonatal outcome following blastocyst transfer and showed an increased 
risk of birth defects compared to cleavage stage transfer (Kallen et al., 2010). In that 
study, also including multiples, any birth defect was defined as all diagnoses with an 
International Classification of Diseases (ICD) code starting with Q. Any birth defect 
was present in 6.9% of infants born following blastocyst transfer and 5.1% of infants 
born following cleavage stage transfer (AOR 1.43, 95% CI 1.14-1.81). In a sub-
group analysis, including only relatively severe birth defects with exclusion of some 
minor and common birth defects with little clinical relevance, the corresponding risks 
were 4.6% and 4.1%, respectively, and the significant difference persisted (AOR 
1.33, 95% CI 1.01-1.75). A Canadian study on 3206 singletons from blastocyst 
transfer did not find any difference in the rates of birth defects between day 2 to 3 
and day 5 to 6 transfers (Dar et al., 2013). The drawbacks on that study are the 
collection of data, mainly via telephone calls or mail to the parents. Finally, no 
difference for birth defects was seen in two systematic reviews and meta-analyses 
including the same four studies with 8737 singletons from blastocyst transfer and 
36,097 singletons from cleavage stage transfer (RR 0.97, 95% CI 0.85-1.12) (Martins 
et al., 2016, Alviggi et al., 2018).  
 
Following extended culture, several studies have reported an altered male-female 
ratio in favor for male (Luna et al., 2007, Chang et al., 2009, Dean et al., 2010, 
Maalouf et al., 2014, Ding et al., 2018, Hattori et al., 2019) as well as a doubled risk 
for monozygotic twinning, from around 1% to 2% per pregnancy (Chang et al., 2009, 
Kawachiya et al., 2011, Ding et al., 2018, Hviid et al., 2018, Hattori et al., 2019, 











Table 4. Preterm birth <37 weeks and very preterm birth <32 weeks following          
blastocyst transfer compared to cleavage stage transfer 
Author 
















No of studies 



















AOR adjusted odds ratio, CI confidence interval, RR relative risk,      
PTB preterm birth <37 weeks, VPTB very preterm birth <32 weeks 
*only fresh cycles  
 
 
Preimplantation genetic testing versus IVF/ICSI 
The number of studies that have investigated the neonatal and maternal outcomes 
following PGT in comparison to IVF/ICSI and SC is limited and most studies include 
small cohorts of children.  
 
When comparing singletons born following PGT-M, PGT-SR and PGT-A to 
singletons born following IVF/ICSI, studies have shown similar or even slightly 
lower rates for PTB and LBW in PGT children (Table 5, including only studies on 
PGT-M and PGT-SR) (Liebaers et al., 2010, Eldar-Geva et al., 2014, Sunkara et al., 
2017, He et al., 2019, Zhang et al., 2019). Likewise, a meta-analysis on four studies 
with 375 singletons following PGT-M/PGT-SR and 24,844 singletons following 
ICSI did not find any significant differences of PTB (AOR 0.85, 95% CI 0.59-1.22) 
(Hasson et al., 2017). As opposed to SC, a Danish study on 149 PGT-M/PGT-SR 
children, reported on a higher risk of PTB (AOR of 1.6, 95% CI 1.0-2.7), following 
adjustment for multiplicity (Bay et al., 2016). Regarding birth defects, the results 
have also been reassuring, with similar risks in comparison to IVF/ICSI (Liebaers et 
al., 2010, Desmyttere et al., 2012, Bay et al., 2016, Hasson et al., 2017, He et al., 
2019, Zhang et al., 2019). However, in the Danish study, inexplicably high rates of 
birth defects were seen (13.5% among PGT children and 8.4% among IVF/ICSI 
children), even though the study included multiples and the follow-up was up to one 
year of age (Bay et al., 2016). 
 





Table 5. Preterm birth <37 weeks and low birth weight <2500 g in  
singletons born following preimplantation genetic testing for monogenic  
disorders and structural rearrangements versus IVF/ICSI 
Author 









PGT-M / PGT-SR vs 
IVF/ICSI 
RR, 95% CI RR, 95% CI OR, 95% CI RR, 95% CI 
No of PGT children 242 149 439 51 
PTB <37 weeks 0.6  
(0.3-1.1) 
1.01            
(0.5-2.0) 
0.7              
(0.5-0.98) 
1.3             
(0.5-3.2) 
LBW <2500 grams 0.4  
(0.2-0.8) 
1.00            
(0.5-2.2) 
0.6              
(0.4-0.9) 
1.02            
(0.4-2.9) 
PGT-M preimplantation genetic testing for monogenic disorders,  
PGT-SR preimplantation genetic testing for structural rearrangements,  
IVF in vitro fertilization, ICSI intracytoplasmic sperm injection,  
RR relative risk, CI confidence interval, OR odds ratio,  
PTB preterm birth <37 weeks, LBW low birth weight <2500 grams 
 
 
Lumping together PGT-M, PGT-SR and PGT-A in studies might, however, cause a 
bias. In general, patients undergoing PGT-M and PGT-SR are not sub fertile while 
PGT-A aims at increasing pregnancy- and live birth rates in elderly women and 
women suffering from recurrent implantation failure and miscarriage by excluding 
aneuploid embryos. In a study, carried out by an Israeli research group, there was a 
lower risk of LBW in the PGT children when comparing 158 PGT-M and PGT-SR 
singletons to 158 IVF/ICSI singletons (Eldar-Geva et al., 2014), a finding that was 
also shown in a later and larger study (Sunkara et al., 2017). These finding might be 
due to the underlying involuntary childlessness among IVF/ICSI patients, while 
patients undergoing PGT-M and PGT-SR are not sub fertile. Subfertility per se also 
affect pregnancy outcome (Pinborg et al., 2013, Luke et al., 2016, Luke, 2017). At 
date, there are no indications that the embryo biopsy per se would have a negative 
impact on the neonatal outcome following PGT.  
 
1.7 Maternal outcome after ART 
Several studies have reported on maternal outcomes following ART. In general, 
placenta-mediated pregnancy complications, including preeclampsia, placental 
abruption and placenta previa seems to be more common in ART pregnancies than 
in spontaneous pregnancies.  
 
 





Regarding hypertensive disorders in pregnancy (HDP), defined as either pregnancy 
induced hypertension or preeclampsia or a combination of both, a higher risk of 
hypertensive disorders in singleton ART pregnancies have been shown when 
compared to singleton pregnancies following SC with an AOR of 1.2-1.5 (Pandey et 
al., 2012, Thomopoulos et al., 2013, Opdahl et al., 2015, Gui et al., 2020). No 
differences for HDP have been seen when comparing IVF and ICSI pregnancies 
separately (Kallen et al., 2005, Buckett et al., 2007, Farhi et al., 2013), neither has 
blastocyst transfer been shown to influence the rate of HDP (Fernando et al., 2012, 
Ishihara et al., 2014, Oron et al., 2015). Unlike ICSI and blastocyst transfer, FET 
seems to be associated with an increased risk of HDP both in comparison to fresh 
transfer and SC (Sazonova et al., 2012, Ishihara et al., 2014, Opdahl et al., 2015, 
Maheshwari et al., 2018). However, prior history of hypertensive disease, an 
important confounder, have not been adjusted for in any of these studies except for 
the study by Farhi et al. (2013). The reasons for the higher incidence of HDP 
following FET has not been clear but recent studies from the United States noted 
higher rates of preeclampsia in pregnancies lacking a CL (von Versen-Hoynck et al., 
2019, von Versen-Hoynck et al., 2020). Likewise, a large Japanese study on almost 
8000 children following a natural cycle and 16,000 children following FET in 
programmed cycles, found a 40% increase in HDP following programmed cycles 
lacking a CL (Saito et al., 2019). In addition to HDP, FET further seems to be 
associated with increased risk for postpartum hemorrhage (PPH) compared to fresh 
transfer and SC and possibly associated with a decreased risk of placenta previa in 
comparison to fresh transfer (Sazonova et al., 2012, Sha et al., 2018).  
 
More than a 3-folded risk for placenta previa and an almost doubled risk for placental 
abruption could be found in two large meta-analyses when analyzing ART versus 
spontaneous pregnancies (Qin et al., 2016, Vermey et al., 2019). In the first of these 
meta-analysis also a 1,3-folded risk for PPH could be seen (Qin et al., 2016). 
Moreover, when comparing ART pregnancies to non-ART pregnancies in sub fertile 
patients a 2,5-folded risk for placenta previa and an almost twofold risk of placental 
abruption was observed in ART pregnancies, suggesting that the ART procedure per 
se might have an effect on placentation (Vermey et al., 2019).  
 
A recently published Nordic register-based study found a doubled risk of placenta 
previa following fresh blastocyst transfer as compared to fresh cleavage stage 
transfer in singletons pregnancies (Spangmose et al., 2019). Other studies on 
singleton pregnancies (Fernando et al., 2012, Ishihara et al., 2014, Oron et al., 2015) 
have not shown any differences in the rate of placenta previa or placental abruption 
 





when comparing blastocyst to cleavage stage transfer in fresh and/or frozen cycles, 
results that are in accordance with a systematic review and meta-analysis 
(Maheshwari et al., 2013). Neither was any differences observed in the study by 
Fernando et al. (2012), including both fresh and frozen cycles, in regards of PPH. In 
all studies adjustment was either made for relevant confounders known to influence 
the obstetric outcome or the study was designed as a matched cohort study.    
              
Studies on maternal outcome in PGT pregnancies are scarce. A retrospective cohort 
study (Hasson et al., 2017) on 51 PGT-M/PGT-SR and 83 ICSI singleton 
pregnancies matched for maternal age and body mass index (BMI) prior to 
pregnancy, showed no differences regarding HDP or in a composite outcome of 
placenta related complications (Hasson et al., 2017). An American study on 177 
singleton pregnancies following PGT including PGT-A, found a 3-folded risk of 
preeclampsia and a 4.5-folded risk of placenta previa when comparing PGT to 
IVF/ICSI pregnancies, whereas the rate of pregnancy induced hypertension and PPH 
was similar following adjustment for several relevant confounders including history 
of hypertensive disease, parity and fresh, frozen natural or frozen programmed cycle 
(Zhang et al., 2019). Additionally, when comparing 149 PGT-M/PGT-SR and SC 
pregnancies, a 9-folded increase in risk of placenta previa was found in comparison 
to SC whereas no difference was found in a sub analysis on PGT versus IVF/ICSI 
pregnancies. In that study, the absolute risk for placenta previa was 3.6% in PGT 
pregnancies, 1.6% in IVF/ICSI pregnancies and 0.3% in spontaneous pregnancies 
and adjustment was made for important confounders including multiplicity (Bay et 
al., 2016).   
 
1.8 Sibling studies 
Both sub fertility and the ART technique including ovarian stimulation and embryo 
culture have been suggested to contribute to the adverse perinatal and maternal 
outcome. In the majority of studies a healthy background population with 
spontaneous pregnancies has been used as a reference group, making it impossible 
to distinguish between the "chicken or the egg", the sub fertility or the ART treatment 
(Berntsen et al., 2019). A time to pregnancy exceeding one year as well as ovulation 
induction without IVF has been shown to increase the risk of PTB as opposed to SC 
(Pinborg et al., 2013, Luke et al., 2017). Some researchers have tried to overcome 
this problem by a study design named sibling studies comparing children born 
following IVF and SC in the same mother. The first sibling study was published in 
 





Lancet in 2008. This Norwegian study on 2546 women with at least one ART 
singleton and one spontaneous singleton did not find any differences in the rate of 
PTB, SGA and perinatal mortality following adjustment for relevant confounders 
including time from previous birth, suggesting that the adverse outcome found in 
ART children could rather be attributable to the underlying infertility than to the 
ART technique (Romundstad et al., 2008). On the contrary, a larger Danish study on 
almost 14,000 sibling pairs examined the perinatal outcomes showing a higher risk 
of PTB and LBW in siblings born following ART compared to SC. Moreover, the 
same study showed that children born following FET were heavier than their siblings 
born from fresh cycles thus suggesting that both patient characteristics as well as the 
ART technique contribute to the outcome  (Henningsen et al., 2011). Adjustments 
were made for known confounders such as maternal age, parity, year of birth and 
child's sex. In another study, the rate of placenta previa was assessed in consecutive 
pregnancies in 1349 women with one pregnancy following SC and another following 
assisted reproduction. Following adjustment for maternal age, parity, prior Cesarean 
section and time interval between pregnancies the AOR was 2.9 (95% CI 1.4-6.1) 
following ART in comparison to SC (Romundstad et al., 2006). In the latest sibling 
study, the authors concluded that a decline in fertility status increases the risks for 
adverse perinatal outcome, irrespective of which ART treatment is used (Luke et al., 
2016). In conclusion, sibling studies indicate that the adverse outcome in ART 
pregnancies is related to both maternal characteristics and the IVF technique per se. 
 
1.9 Trends over time 
When comparing perinatal outcomes over time a significant improvement has been 
noticed. The trend toward SET leading to fewer multiple births has contributed to the 
improvement but also for singleton births the rate of PTB, LBW and SGA has 
declined considerably over the last decades as shown in a large Nordic population-
based matched cohort study on 92,000 ART and half a million spontaneously 
conceived children. In the Nordic study, the rate of PTB and SGA declined by half 
in ART singletons during 1988-2007, a trend that was not seen in SC (Henningsen 
et al., 2018). A single center study from the United Kingdom, showed a significant 
increase in birth weight in IVF singletons over a time period of 25 years, a trend that 
has not been seen in spontaneous pregnancies (Castillo et al., 2019). To determine 
trends in the rate of birth defects, the Committee of Nordic ART and Safety 
(CoNARTaS) group investigated the risks of major birth defects between 1988 and 
2007. The number of children diagnosed with a major birth defect increased over the 
 





years in both ART and SC pregnancies, considered to be a consequence of better data 
quality, yet the relative risk of being born with a major birth defect following ART 
in comparison to SC did not change over the time period (Henningsen et al., 2018).  
 
When investigating maternal outcomes the rate of placenta previa has increased 
among ART pregnancies during the last 30 years, a trend that has not been observed 
for spontaneous pregnancies and results that remained significant when restricting 
analyses to nulliparous women. For HDP, no clear trend has been found whereas the 
rate of placental abruption has decreased in both IVF and SC pregnancies (Petersen 
et al., 2020). This study from the CoNARTaS group included almost 7 million 
pregnancies of which almost 150,000 were conceived through ART.  
 
1.10 Long-term health of children born following ART 
While the neonatal outcome of ART is well documented, large studies on long-term 
follow-up are scarce. Since the intrauterine milieu has been suggested to influence 
long-term health, as described by the Barker hypothesis, follow-up studies on ART 
children are warranted (Barker et al., 1993). Even though the number of ART 
children is growing rapidly, the vast majority are still young and drawing conclusions 
on life-time risks is thus hard at date. However, there are some studies published on 
health for children and adolescents following ART.  
 
Cardiovascular risks 
Several risk factors for the future development of cardiovascular diseases (CVD) 
have been described. Some of the risk factors for developing metabolic syndrome 
and CVD, e.g. PTB, LBW and SGA, are also associated with ART (Barker et al., 
1993, Helmerhorst et al., 2004, Jackson et al., 2004, McDonald et al., 2009, Pandey 
et al., 2012, Pinborg et al., 2013, Qin et al., 2017). Further, the risk of HDP is 
elevated following ART (Sazonova et al., 2012, Thomopoulos et al., 2013, Ishihara 
et al., 2014, Opdahl et al., 2015, Chen et al., 2016, Maheshwari et al., 2018), not 
least in frozen cycles, thus ART might also be a potential risk factor for the 
development of CVD in the offspring. A meta-analysis including 36 studies on 
53,000 individuals showed that in utero exposure to preeclampsia was associated 
with a 5.17 mm Hg higher mean systolic and 4.06 mm Hg higher mean diastolic 
blood pressure as well as a slightly higher (0.36 kg/m2) mean BMI in children and 
young adults (Andraweera and Lassi, 2019). Both elevated blood pressure and 
changes in body composition have been found after ART in a few studies (Ceelen et 
 





al., 2009, Scherrer et al., 2015, Meister et al., 2018) and summarized in systematic 
reviews and meta-analyses (Hart and Norman, 2013, Guo et al., 2017). In the study 
by Meister, vascular function was reassessed in 54 ART children and 43 age- and 
sex-matched controls born following SC five years following the initial assessment. 
The mean age of the adolescents examined were 17 years in both groups. The 
reassessment revealed persisting premature vascular aging in the ART children and 
increased blood pressure (Meister et al., 2018).   
 
Type 1 diabetes 
ART has been shown to alter the glucose metabolism in mice and in children (Ceelen 
et al., 2009, Chen et al., 2014, Vrooman and Bartolomei, 2017). Two Danish studies 
comparing children born to sub fertile parents or parents undergoing infertility 
treatment found no association between fertility status and/or fertility treatment and 
type 1 diabetes (Hargreave et al., 2016, Kettner et al., 2016). A newly published large 
Swedish cohort study on 48,000 ART singletons and 3 million spontaneously 
conceived singletons investigated the development of type 1 diabetes. In the 
unadjusted analysis there was an increased risk for type 1 diabetes following ART, 
yet when adjusting for confounders including parental diabetes, no significant 
difference was found in the main analysis. In sub-analyses on singletons after frozen 
versus fresh transfer and singletons after frozen transfer versus SC, significantly 
higher risks of type 1 diabetes were observed following FET (hazard ratio [HR] 1.52, 
95% CI 1.08-2.14 and HR 1.41, 95% CI 1.05-1.89, respectively) whereas ICSI versus 
IVF in fresh cycles did not seem to affect the risk of developing type 1 diabetes 
(Norrman et al., 2020). The reason for the higher risk for developing diabetes 
following FET might be due to larger babies, also shown to be a risk factor for 
diabetes later in life (Haynes et al., 2007, Ievins et al., 2007).  
 
Cancer 
In a large cohort study including just above 100,000 children born in Britain after 
ART and with a mean follow-up time of seven years, no increase in the overall risk 
of cancer was found (Williams et al., 2013). Accordingly, in an almost equally large 
Nordic study with a mean follow-up of ten years, similar risks for overall cancer was 
observed (Sundh et al., 2014). A systematic review and meta-analysis including 16 
cohort and 13 case-control studies, showed an increased risk for overall cancer (RR 
1.16, 95% CI 1.01-1.32), hematological malignancies (RR 1.39, 95% CI 1.21-1.60) 
and other solid tumors (RR 1.57, 95% CI 1.14-2.16) when comparing ART offspring 
to non-ART offspring (Wang et al., 2019). In a later large retrospective study from 
the United States, including almost 300,000 ART children and above 2 million non-
 





ART controls, there was no difference for overall cancer risk in the first decade of 
life, yet an association between ART and embryonal tumors, in particular hepatic 
tumors (HR 2.46, 95% CI 1.29-4.70) (Spector et al., 2019). A recent Danish cohort 
study, including 37,000 ART children born during 1996 to 2012, showed no 
association between any type of childhood cancer and any ART treatment or use of 
any type of fertility drugs in comparison to children born from fertile women. 
However, based on 14 cases, an increased risk of childhood cancer following FET 
was reported (incidence rate difference 26.9 [95% CI 1.28-51.0] per 100,000), 
mainly due to the elevated risk for leukemia and sympathetic nervous tumors 
(Hargreave et al., 2019).   
 
Altogether, studies show some divergent results. Differences have mainly been found 
in subgroups of patients and for specific types of malignancies. Regarding FET and 
cancer risk, some studies have shown an association between high birth weight, more 
common following FET, and an increased risk of especially leukemia but possibly 
also Hodgkin’s lymphoma (Roman et al., 2013, Crump et al., 2015, Petridou et al., 
2015, Triebwasser et al., 2016, Groves et al., 2018). However, further studies are 
warranted to elucidate this association.  
 
Cerebral palsy 
For cerebral palsy, a Swedish study on 5680 singletons, not adjusting for gestational 
age, found a 2.8-folded risk following IVF (Stromberg et al., 2002) whereas a larger 
Danish study on 33,139 IVF singletons and multiples reported similar risks following 
adjustment for multiplicity and gestational age (Hvidtjorn et al., 2011). Both studies 
presented an incidence of approximately 2 per 1000 for singletons. In a smaller study, 
a doubled risk for cerebral palsy was seen following fresh transfer in comparison to 
non-ART singletons, yet no adjustment was made for gestational age (Pinborg et al., 
2010). The fact that children born following a fresh transfer are more prone to PTB 
as well as the results in the study by Hvidtjorn et al. could suggest that the increased 
risk for cerebral palsy is driven by the higher incidence of PTB rather than the 
treatment or the infertility per se (Hvidtjorn et al., 2011).  
 
Neurodevelopment, cognitive health and school performances 
Considering the elevated risks for PTB and LBW following ART also neurodevelop-
ment and cognitive health is of great interest. 
 
A Swedish cohort study found a 4-folded increase for developmental delay following 
IVF in comparison to SC but when restricting the analyses to singletons, the 
 





significance disappeared (Stromberg et al., 2002). Other studies have also shown 
comparable results for neurodevelopment in ART and SC children. A Danish study, 
adjusting for multiplicity, showed no differences in mental retardation (Bay et al., 
2013) and neither was any differences seen in a Swedish study when restricting the 
analysis to singletons (Sandin et al., 2013). In a European collaboration study, 
including a substantial number of singletons from five European countries, no 
differences regarding cognitive and motor development were found when comparing 
424 IVF, 511 ICSI and 488 SC children (Ponjaert-Kristoffersen et al., 2005). Finally, 
a systematic review and meta-analysis summarized studies on cognitive development 
following different ART techniques concluding that, at date, there is some evidence 
to suggest that ICSI might influence cognitive health yet, most studies on the subject 
suffer from methodological limitations (Rumbold et al., 2017). Among high-quality 
studies, there was no difference in cognitive outcome among children born following 
conventional IVF and those conceived spontaneously. Findings among high-quality 
studies of children conceived with ICSI were, however, inconsistent in comparison 
to IVF and ranged from no differences observed in intelligence quotient (IQ) scores 
to a 50% higher risk of severe intellectual disability.  
 
Further, four large Nordic population-based studies on school performances in 
children at age 15-16 years have been published in the last couple of years. Giving 
the fact that all children, with a few exceptions, attend school in the Nordic countries, 
school performances is a good way of assessing cognitive development. In a Swedish 
study, on 8323 ART children and almost 1.5 million spontaneously conceived 
children, higher total mean scores were seen in ART singletons compared to SC 
singletons in the crude analysis. When adjusting for relevant confounders, the total 
mean score was, however, significantly lower in the ART singletons but not 
considered to be clinically relevant (Norrman et al., 2018). A Danish study showed 
similar results (Spangmose et al., 2017). The third study, performed by the same 
Danish study group, showing no significant differences in performance, compared 
children born following FET (n=423) and fresh transfer (n=6072) (Spangmose et al., 
2019). The latest Swedish study compared ICSI singletons (n=6953) to IVF 
singletons (n=11,713) and spontaneously conceived singletons (n=2,022,995). 
Similar school results were seen for IVF and ICSI children. Compared to children 
born after SC, small differences were observed in the 3rd grade in favor of SC 
children whereas no differences between ICSI and SC children were observed in the 
9th grade (Norrman et al., 2020). Overall the differences are small and probably not 
of clinical relevance.  
 
 





Autism spectrum disorders and attention deficit hyperactivity disorder 
Concerns have been raised whether there is an association between ICSI and autism 
spectrum disorders (ASD). The findings are, however, still inconclusive. A study on 
ART children in California in 1997-2006 with a five year observational time found 
an association between ICSI singletons in fresh cycles and ASD (Kissin et al., 2015). 
In this study it was also shown that among the children with ASD, a greater 
percentage was of male sex, born in a multiple birth and more often also born preterm 
or with LBW. In contrast to the Californian study, a large Danish cohort study did 
not find any association between ICSI and ASD (Bay et al., 2013). A meta-analysis 
published three years ago including around 8 million children in 11 studies, revealed 
an increased risk of ASD following any ART treatment (RR 1.35, 95% CI 1.09-1.68) 
but in a subgroup analyses on singletons, no difference was seen (Liu et al., 2017). 
Regarding attention deficit hyperactivity disorder (ADHD), a Swedish study 
suggested a slight increase following ART. Though, when adjusting for length of 
infertility or restricting the analysis to singletons only, the statistical significance was 
lost (Kallen et al., 2011). Additionally, a greater risk for ADHD was reported in 
children born to women with fertility problems in comparison to children born to 
fertile women but without adjustment for multiplicity (HR 1.36, 95% CI 1.29-1.45) 
(Svahn et al., 2015).  
 
In summary, both regarding ASD and ADHD, diseases involving both genetic and 
environmental factors, there might be a slight increase following ART treatment. 
Noteworthy, in the majority of studies the risk differences disappeared when 
restricting the analyses to singletons. 
  
 












2 AIMS OF THE THESIS 
General aim 
The aim of this thesis is to evaluate the risks for the children born through ART and 
the mothers undergoing ART with advanced techniques.  
 
Specific aims 
➢ To analyze the neonatal and maternal outcome after blastocyst transfer 
(day 5-6) compared to cleavage stage transfer (day 2-3) and SC.  
➢ To compare the obstetric outcome after FET depending on protocol 
used. Additionally, we compare FET to fresh transfer and SC.  
➢ To investigate neonatal and maternal outcome following transfer of 
vitrified blastocysts in comparison to slow-frozen cleavage stage 
embryos and fresh blastocysts.    
➢ To study neonatal, maternal and early childhood outcomes following 
PGT in Sweden compared to children born after IVF/ICSI and SC.   
  
 












3 PATIENTS AND METHODS 
All four papers included in this thesis were carried out as retrospective population-
based register studies. The majority of Swedish health care is publicly financed and 
for a lot of diseases and conditions the quality of the care is followed through 
nationwide health- and quality registers. In Sweden, two types of national registers 
including information on health outcome are used. The National Board of Health and 
Welfare manage the health registers whereas National Quality Registers are managed 
by the Swedish Association of Local Authorities and Regions (SKR). For the health 
registers run by the National Board of Health and Welfare, regulated by the Health 
Data Law, reporting is compulsory for all care providers and the patients have no 
possibility to ask for their data to be withdrawn. Regarding the National Quality 
Registers, regulated by the Patient Data Law, participation is voluntary. Registers 
run by the National Board of Health and Welfare used in this thesis are: the MBR-
IVF, the MBR, the National Patient Register (NPR), the Register of Birth Defects, 
the Prescribed Drug Register and the Cause of Death Register. Of the nearly 100 
Quality Registers in Sweden, two were used in this thesis: the Q-IVF and the Swedish 
Neonatal Quality Register (SNQ). Due to the PIN given to every legal citizen in 
Sweden, but also other Nordic countries, it is possible to cross-link these registers 
thus enabling epidemiological research (Ludvigsson et al., 2009). For all Nordic 
countries, the PIN is given either at birth or at immigration.  
 
An overview of the study cohorts and registers used in the different papers is 


















3.1 Settings and study design 
 
Table 6. Study settings and study populations 
 Paper I Paper II Paper III Paper IV 
Setting Population-based register study 
Study 
design 
Retrospective register study 
Countries Sweden Sweden Sweden and Denmark Sweden 
Study 
period 






All singletons born 
following blastocyst 
transfer (n=4813) 





cycles in FET 
All singletons born 
following transfer of 
vitrified blastocysts 
(n=3650) 




All singletons born 
following cleavage 
stage transfer      
(n=25,747) 
 
All singletons born 
following SC                
(n=1,196,394) 
 
All singletons born 
following fresh embryo 
transfer     
(n=24,365) 
 
All singletons born 
following SC               
(n=1,127,566) 
All singletons born 
following transfer of 
slow-frozen cleavage 
stage transfer (n=8123) 
 
All singletons born 
following transfer of 
fresh blastocysts 
(n=4469) 
All singletons born following 
IVF/ICSI (n=55,355) 
 
Singletons born following SC,     
(n=26,535). One hundred matched 
controls per PGT child. Matched for 
year of birth of child, maternal age 
(+/- 5 years), parity and delivery 
hospital. In five cases we did not 
find 100 controls per PGT child, 
these PGT children had 41, 64, 66, 
68 and 96 controls each.  
Registers Q-IVF, MBR-IVF, 
MBR, NPR, Register of 
Birth Defects 
Q-IVF, MBR-IVF, MBR, 
NPR, Register of Birth 
Defects, SNQ, Prescribed 
Drug Register 
CoNARTaS cohort 
based on the Swedish 
and Danish ART-
registers, MBRs and 
NPRs 
Q-IVF, MBR-IVF, MBR, NPR, 










Male gender, PTB, 
VPTB, EPTB, LBW, 
VLBW, macrosomia, 





VPTB, EPTB, post term 




mortality, major birth 
defects, placenta previa, 
placental abruption 
VPTB, post term birth 
(≥42 weeks), VLBW, 
SGA, LGA, 
perinatal/neonatal 
mortality, any birth 
defects, placenta previa, 
placental abruption 
VPTB, post term birth (≥42 weeks), 
VLBW, macrosomia, SGA, LGA, 
perinatal/neonatal/infant mortality, 
any and major birth defects at birth, 
HDP, placenta previa, placental 
abruption, PPH.  
Early childhood outcomes: asthma, 
allergic disorders, sepsis, 
hypothyroidism, ADHD, ASD,  
affective disorders, schizophrenia, 
mental retardation, cerebral palsy, 
epilepsy, mortality 
FET frozen embryo transfer, PGT preimplantation genetic testing, IVF in vitro fertilization,                    
ICSI intracytoplasmic sperm injection, SC spontaneous conception, Q-IVF National Quality Register for 
Assisted Reproduction, MBR Medical Birth Register, NPR National Patient Register, SNQ Swedish 
Neonatal Quality Register, CoNARTaS Committee of Nordic ART and Safety, ART Assisted Reproductive 
Technology, PTB preterm birth <37 weeks, VPTB very preterm birth <32 weeks, EPTB extreme preterm 
birth <28 weeks, LBW low birth weight <2500 grams, VLBW very low birth weight <1500 grams,           
HDP hypertensive disorders in pregnancy, SGA/LGA small/large for gestational age, PPH postpartum 
hemorrhage (>1000mL), ADHD attention deficit hyperactivity disorder, ASD autism spectrum disorders 
 





3.2 Data sources 
For register-based studies in Sweden, ethical permission from the Ethical Review 
Authority is required. Following ethical approval, an application is sent to the 
National Board of Health and Welfare providing a support service for all registers 
and researchers. This application shall contain information on which health - and 
quality registers should be included in the data set but also all variables the 
researchers request shall be listed. Following a disclosure, all requested registers are 
cross-linked by the National Board of Health and Welfare using the PIN and 
subsequently, the researcher get a pseudoanonymized data set with serial numbers 
instead of PIN. A key containing the PINs is stored at the National Health and 
Welfare for three years enabling updates in the data file in case of longitudinal 
studies.  
 
In Sweden ICD 9 codes were used through 1996 and ICD 10 codes from the 
beginning of 1997.  
 
 
The MBR-IVF and Q-IVF 
Following the birth of the first ART child in Sweden in 1982 and until 2006, all ART 
cycles were annually reported to the National Board of Health and Welfare as 
aggregated data. Further, for research purpose, identified data for all cycles resulting 
in deliveries were collected by the National Board of Health and Welfare at four 
occasions during 1982 and 2006 and stored in a separate file named MBR-IVF in 
this thesis.  
 
In 2007, the Q-IVF was established to collect nationwide, identified data on all ART 
treatments. All public (n=6) and private (n=13) IVF clinics in Sweden report 
individual data with full identification to the register and the results are public and 
published at the website (www.qivf.se). The ART registers include full identification 
of the mother, information on donated or autologous gametes, number of oocytes 
retrieved, fertilization method (IVF or ICSI), culture duration, treatment (fresh or 
frozen-thawed transfer), freezing method (vitrification or slow-freeze), date of 
embryo transfer, number of embryos transferred, number of gestational sacs at first 
ultrasound and date of delivery as well as number of children born. Since 2014 also 
complications to ART treatment are registered. In addition to medical results, the Q-
IVF also collect data on patient satisfaction via questionnaires. Five variables are 
 





assessed and the results published on the web page at clinic level. The patients are 
informed about the Q-IVF and may choose to opt-out, although this is very rare. 
Subsequently, the coverage rate is very close to 100%.  
 
 
The Swedish MBR 
MBR started in 1973 as an act of Swedish parliament and its basic structure has 
remained the same since the start even though major modifications has taken place, 
especially in the way data are collected (MBR). Initially, a Medical Report was filled 
in by the secretaries at each unit, these reports were mainly used for communication 
between the antenatal, the delivery and the pediatric/neonatal units. However, one 
copy of the report, containing only information that was considered relevant for the 
register, was sent to the National Board of Health and Welfare for registration. 
Today, the process is computerized and the information is based on information 
recorded at maternity care units, delivery wards and pediatric examinations of the 
newborn by filling in standardized medical records. It is mandatory for all health care 
providers to report to the MBR. Approximately 115,000-120,000 children are born 
in Sweden annually, MBR covering the vast majority of these. A summary 
publication of the content and quality of the Swedish MBR published in 2003 by the 
Centre of Epidemiology (EpC), reported that 1-3% of infants were completely 
missing, for some others there might be some missing data owing to incomplete 
records from the antenatal units and pediatric wards (Research Report from Centre 
for Epidemiology (EpC), 2003). Every year, infants reported to the MBR are 
compared with infants reported to Statistics Sweden (SCB) and in case of missing 
data in the MBR, a request on obtaining copies of the medical records are sent to the 
health care provider, however, not always successfully. Reasons for complete 
missing data in the MBR might be emigration or incomplete reporting from the 
health care providers.  
 
The quality of the register has been investigated at three times, in 1976, 1988 and in 
2001 with the first two evaluations summarized in a publication from 1990 by 
Cnattingius et al. (Cnattingius et al., 1990, Research Report from Centre for 
Epidemiology (EpC), 2003). In these quality controls the original medical records 
were compared to the data in the register but also to information available at the SCB, 
and the MBR was shown to have high validity.  
 
 





The MBR contains data on maternal characteristics i.e. age, parity, BMI, smoking 
habits, years of involuntary childlessness, all recorded at first antenatal visit at the 
maternity unit. Moreover, data on delivery and neonatal outcomes including child´s 
sex, birth weight, gestational age, Apgar score and stillbirth/live birth is included. In 
addition, maternal complications such as HDP, PPH, lacerations as well as mode of 
delivery is recorded. Both click-boxes and ICD codes can be used for the neonates 
and the mothers.  
 
According to the Summary Report in Swedish in 2002 (Forskningsrapport från 
Epidemiologiskt Centrum (EpC), 2002), published in English in 2003 (Research 
Report from Centre for Epidemiology (EpC), 2003), the registration on PIN for both 
mothers and infants, gestational age, birth weight and incidence of birth defects is 
fairly reliable. For maternal smoking, information on smoking at first antenatal visit 
is missing in 4-9%. Maternal pre-pregnancy weight and length are recorded at the 
first visit to the antenatal unit during the first trimester, with missing data in 20-30% 
of cases. Hence, BMI is possible to calculate in 65-85%. No involuntary 
childlessness was stated in almost 94% of pregnancies. Parity seems to be incorrect 
in 9% of cases, yet well documented in women who have not immigrated. In the 
majority of the incorrect cases, the first birth in the MBR is by mistake listed as the 
first child even though the woman has one or several deliveries abroad. Regarding 
mode of delivery, Cesarean section is not recorded in around 2% of cases. When 
comparing these figures to the information available for our studies with missing 
information on smoking in 4-6% and on BMI in 6-10% we might assume that the 
quality of the Swedish MBR has not declined in the last decade. For BMI, there is of 
course a risk that the heaviest women, not wanting their weight to be recorded, cause 
a bias especially in the spontaneous group. Additionally, women with BMI >35 are 
not offered publicly funded ART treatment even though national guidelines on BMI 
limits do not exist and different policies are adopted in different county councils but 
also on a clinic level.  
 
 
The Swedish NPR 
In the 1960's the National Board of Health and Welfare started to collect information 
regarding inpatient care at public hospitals, registered in the NPR (NPR). Since 1984 
the participation is mandatory for all county councils. From 1987 NPR includes all 
inpatient care in Sweden. Following 2001 the register also covers outpatient visits 
including day surgery and psychiatric care from both private and public caregivers. 
 





The NPR is divided into the In Patient Register, also called the Hospital Discharge 
Register and the Out Patient Register. The coverage rate of the In Patient Register is 
almost 100% whereas it is considerably lower for the outpatient part (80%). Primary 
care is not covered in the NPR. The register is based on ICD codes and also includes 
information on hospital, age, gender, admission and discharge dates. The NPR has 
been shown to have high validity (Ludvigsson et al., 2011).  
 
 
The Register of Birth Defects 
The Register of Birth Defects and chromosomal abnormalities (formerly Register of 
Congenital Malformation) (www.socialtyrelsen.se/en), established in 1964 in 
conjunction with the Thalidomide scandal, contains information on anatomical 
defects and chromosomal abnormalities according to ICD codes. Birth defects are 
supposed to be reported to the register at birth, at latest within a month from date of 
birth. Since 1999 the register also include data on induced abortions following pre-
natal screening and the detection of malformations, however, without the women’s 
PIN due to legal regulations in Sweden regarding identification and abortion. 
According to the latest report the coverage rate on birth defects in born children is 
good. However, missing data on induced abortions due to malformations is rather 
high, yet considered random (Annual report Register of Birth Defects, 2018).  
 
 
The Prescribed Drug Register 
The Prescribed Drug Register (www.socialtyrelsen.se/en) was established in 2005 
and, based on anatomic therapeutic chemical (ATC) codes, includes information on 
all purchased prescription drugs. Besides ATC codes, the register contains 
information on the patient’s PIN, gender, age, prescription amount as well as date 
for prescription and date when the drugs are purchased. Data are collected 
electronically with little missing data. Medications used in inpatient care are not 




The SNQ was founded in 2001 and collects data for infants admitted to neonatal units 
during the first four postnatal weeks (SNQ). All pediatric hospitals in Sweden with 
a neonatal unit (n=37) are affiliated to SNQ. The register contains data on 34 
interventions and information on 25 outcomes ranging from infant mortality and 
 





neonatal morbidity to health at follow-up. The registration of health at follow-up 
started in 2016 and covers children with complicated neonatal periods such as 
extremely preterm birth (<28 weeks), children with hypoxic-ischemic encephalo-
pathy and meningitis. Moreover, parental reported experience measures are included. 
The register has been shown to have excellent completeness and high validity 
(Norman et al., 2019).  
 
 
The Cause of Death Register 
From 1961 the Cause of Death register (www.socialtyrelsen.se/en) is updated 
annually based on the medical death certificate. The medical death certificate is filled 
in by the physician and sent to the National Board of Health and Welfare within three 
weeks of death. The underlying cause/causes of death are given according to the ICD 
system.  For the years 1952-1960 there is a historical register collected retro-
spectively from medical records. Until 2011 only Swedish citizens, including death 
abroad, were registered but following 2012 also foreign residents dying in Sweden 
are registered. The number of deaths registered is considered complete. However, a 
small proportion of deaths are lacking the information on cause of death. In summary, 
the register is considered of high quality (Brooke et al., 2017).   
     
                                                           
Statistics Sweden (SCB) 
SCB is a national administrative authority and responsible for official statistics 
including, for example, information on income, socio-economic conditions, 
educational level and foreign background. In addition, population statistics show 
both population size and changes such as number of children born and number of 
deaths but also information on both emigration and immigration (SCB).  
 
 
The CoNARTaS cohort  
CoNARTaS was established in 2008 and is a Nordic collaborative research group 
(www.conartas.com). Information on the Danish, Finnish, Norwegian and Swedish 
ART patients in ART registers or ART databases has been linked to MBRs to 
determine ART deliveries. Furthermore, linkage has been made to other national 
health registers, disease-specific quality registers and other nationwide databases. 
Data are linked at an individual level owing to the PIN given to every legal citizen 
in the Nordic countries. Data linkage has been performed twice, the first covering 
 





years 1982-2007 with four spontaneous controls from the MBR for each ART child 
within their own country and the second 1985-2015 including all children in the 
MBRs. However, due to differences in availability of data on ART conception in 
each country some differences for the coverage period exist between the countries 
(Opdahl et al., 2019). In paper III the data from the second data linkage were used. 
At the moment the cohort consist of  170,000 ART children, live and still born, and 
7.7 million spontaneously conceived children as well as 130,000 mothers with at 
least one delivery after ART and 4 million mothers with deliveries only following 
SC during 1984 through 2015 (Opdahl et al., 2019). The Nordic countries are 
comparable in terms of demography, health care and social security systems 
including reimbursement of ART treatment, which enables analyses on pooled data. 
Initially, the database was set up to study perinatal health in ART offspring. At date, 
the aim is also to study pregnancy complications for the mothers as well as long-term 
health for the children in terms of diabetes, CVD, cancer, mental health, puberty 
problems and imprinting disorders. In addition, long-term morbidity for the mothers, 
such as cancer and cardiovascular disease, can be assessed.  
 
3.3 Definitions of birth defects 
Several definitions for birth defects can be used. According to the ICD system, ICD 
9 codes 740-759 A-X and ICD 10 codes beginning with Q involves birth defects, 
deformations and chromosomal abnormalities. Major birth defects are those defects 
that in general cause functional impairment and/or require surgical repair whereas 
minor defects are considered of little clinical relevance, yet sometimes also require 
surgical correction (e.g. tongue tie). EUROCAT, founded in 1979, is a European 
network of population-based registers for epidemiological surveillance of birth 
defects. The main objective of the network is surveillance on congenital anomalies, 
mainly in Europe. Several countries report anonymous data to EUROCAT for 
surveillance and research purpose (Tucker et al., 2018). Besides, the EUROCAT 
classification system differentiates between major and minor malformations and is 
updated with regularity. All minor birth defects with limited clinical impact that 
should be excluded are listed according to ICD codes (www.eurocat-network.eu).  
 
In Sweden, birth defects are recorded at birth in both the MBR and in the Register of 
Birth Defects following the pediatric examination of the newborn at the delivery unit. 
Birth defects that are detected during childhood are recorded in the NPR. The 
following definitions and registers have been used for birth defects in this thesis:  
 






Paper I: Major birth defects; all ICD 10 codes beginning with Q but with exclusion 
of minor defects with little clinical relevance. The same classification system has 
been used in previous Swedish studies and the exclusion is based on "conditions that 
are relatively common, variable in registration, and sometimes associated with 
preterm birth and low birth weight. The following such conditions that are excluded: 
preauricular appendix, patent ductus arteriosus at preterm birth (<37 weeks), single 
umbilical artery, undescended testicle, congenital hip (sub) luxation, and minor skin 
malformations (mainly nevus). The remaining malformations are classified as 
“weeded” and will contain mainly major malformations but also some less severe 
conditions" (Kallen et al., 2005). Birth defects were recorded up to one year of age 
using the Swedish MBR, the Register of Birth Defects and the Swedish NPR.  
 
Paper II: Classification of major birth defects according to EUROCAT. Birth defects 
were recorded up to one year of age using the Swedish MBR, the Register of Birth 
Defects and the Swedish NPR. 
 
Paper III: Any birth defects with an ICD 10 code beginning with Q were included, 
i.e. both major and minor birth defects. Only birth defects at birth were recorded 
using the CoNARTaS cohort.  
 
Paper IV: Any birth defect with an ICD 9 code 740-759 or ICD 10 code beginning 
with Q at birth were included, i.e. both major and minor birth defects. Moreover, we 
report major birth defects at birth according to EUROCAT separately.  
 
3.4 Statistical analyses 
Statistical analyses for Paper I were done in collaboration with Karin Källen, PhD 
statistics, Professor, Department of Reproduction Epidemiology, Tornblad Institute, 
Institution of Clinical Science, Lund University, Lund, Sweden. The analyses were 
conducted by using software Gauss (Gauss TM, Aptech Systems Inc, Maple Valley, 
WA, USA, http://www.aptech.com). For Paper II-IV, the statistical analyses were 
done in collaboration with Max Petzold, PhD biostatistics, Professor, Swedish 
National Data Service & Health Metrics Unit, University of Gothenburg, 
Gothenburg, Sweden. Software STATA version 15 and SPSS version 24 and version 
26 were used for the analyses.  
 
 





Descriptive statistics are given by number (n) and percentages for categorical 
variables and by mean and standard deviation (SD) or median and interquartile range 
(IQR) for categorical variables.  
      
For all four papers, logistic regression analyses were used to examine the association 
between exposure and outcome. The results from the regression analyses are 
presented as crude as well as adjusted ORs, i.e. uni- and multivariable logistic 
analyses. Two-sided tests were used and the significance level was set to 0.05. 
Corresponding 95% CI are presented. In paper IV, to assess the risks of adverse early 
childhood outcome, Cox-regression was used to calculate the HRs. Adjustment was 
made for known and possible covariates as listed in Table 7.  
 
A summary on statistical methods used in the different papers is presented in  
Table 7.  
 
Logistic regression could be used to analyze how one or several predictors 
(independent variables) are associated with an outcome (dependent variable). The 
predictors can be either continuous or categorical while the outcome variable is 
binary/dichotomous (yes/no, sick/healthy etc.). The result of a regression analysis is 
presented as OR and 95% CI. Odds is the probability of a certain event to occur 
divided by the probability of a certain event not to occur and the OR is the ratio 
between odds. A logistic regression analysis, both in its simple and its multivariable 
form, does not require enormous data sets. A "rule of a thumb" has suggested ten 
events per added independent variable, however, this rule is by some considered too 
conservative suggesting 5-9 events per independent variable (Vittinghoff and 
McCulloch, 2007). In a regression analysis, the independent variables should not be 
correlated causing multicollinearity and can be checked by calculating the Pearson´s 
or Spearman´s correlation coefficient.  
 
Cox-regression, or the Cox proportional-hazards model, is used in time-to-event 
analysis, also called survival analysis. A time scale is added in the regression analysis 
with a starting point when the observations enter the study and an ending either when 
a certain event occur, at emigration, death or end of follow-up, whichever occur first. 
The hazard rate is the number of cases of a specified outcome per population at risk 
per unit of time. The HR is the ratio between hazards and can be explained as the 
probability of an event in one group divided by the probability of an event in another 
group occurring at a given interval of time. A HR >1 means that the event is more 
likely to happen whereas a HR <1 means it is less likely to occur. A HR of one 
 





indicates that both groups experience an equal risk for the event at any point of time, 
i.e. the exposure has no effect on the outcome over time. 
 
Table 7. Overview on statistical methods  










Year of birth, maternal age, 
parity, maternal smoking, 
maternal BMI, years of 
involuntary childless-ness, 
child´s sex. 





Uni- and multivariable logistic regression analysis, OR and AOR with 95% CI Uni- and multivariable 
logistic regression 
analysis, OR and AOR 
with 95% CI 
Uni- and multivariable 
Cox-regression, HR and 
adjusted HR with       
95% CI 
Covariates When comparing blastocyst 
and cleavage stage transfer 
adjustment was also made 
for number of oocytes 
retrieved, number of 
embryos transferred and for 
fresh or frozen transfer. 
 
In sub analysis on birth 
defects during 2008-2013 
adjustment was moreover 
made for IVF or ICSI. 
Year of birth, maternal age, parity, 
maternal smoking, maternal BMI, 
years of involuntary childless-ness, 
child´s sex, level of maternal 
education, chronic hypertension. 
 
For comparison between ART 
pregnancies adjustment was also 
made for cause of infertility, IVF/ 
ICSI, culture duration and number 
of gestational sacs.  
 
For programmed and stimulated vs. 
natural cycles adjustment was 
moreover made for freezing 
method (vitrification or            
slow-freeze). 
Child´s country 













SET, number of 
gestational 
sacs. 
Year of birth, maternal 
age, parity.  
 
When comparing PGT to 
IVF/ICSI, adjustment 
was also made for fresh 
or frozen transfer.  
 
For early childhood 
outcome adjustment was 
made for year of birth, 
maternal age, parity and 
smoking 
Missing data Replaced by overall mean 
for smoking and BMI. 
 
Set as 0 for years of 
involuntary childlessness 
Missing data was not imputed. Missing data 
was not 
imputed. 
No missing data for 
confounders used for 
regression analysis. 
SD standard deviation, IQR interquartile range, OR odds ratio, AOR adjusted odds ratio,              
CI confidence interval, HR hazard ratio, BMI body mass index, IVF in vitro fertilization,           
ICSI intracytoplasmic sperm injection, ART assisted reproductive technology, SET single     
embryo transfer, PGT preimplantation genetic testing 
  
 






All studies were approved by the Regional Ethical Review Board in Gothenburg.  
Ethical approval for paper I: Dnr 304/06, T876-14.  
Ethical approval for paper II: Dnr 304/06, T109-08, T087-12 and Dnr 214-12, 
T422-12, T516-15, T233-16, T300-17, T1144-17, T121-18.                  
Ethical approval paper III: Dnr 304/06, T T109-08, T087-12 and Dnr 214-12, 
T422-12, T516-15, T233-16, T300-17, T1144-17, T121-18.  
Regarding Danish data, ethical approval is not required for register-based 
research.     









4 RESULTS AND COMMENTS 
4.1  Paper I 
Neonatal and maternal outcome after blastocyst transfer: a 
population-based registry study. 
During 2002-2013, 4819 singletons were born following blastocyst transfer, 25,747 
singletons following cleavage stage transfer and 1,196,394 singletons following SC 
in Sweden.  
 
Neonatal outcome      
Birth defects and other neonatal outcomes are summarized in Table 8, 9 and 10. Birth 
defects were defined according to ICD 10 codes beginning with Q. Minor birth 
defects such as preauricular appendix, tongue tie, patent ductus arteriosus in preterm 
infants, single umbilical artery, undescended testicle, hip luxation/ subluxation, 
clicking hip and nevus were excluded. 
 
 
Table 8. Birth defects in singleton pregnancies after blastocyst transfer, cleavage stage 
transfer and spontaneous conception in Sweden 2002-2013. 
Outcome Blastocyst 




stage transfer    
                            
n=25,747 
SC          
     
                      
n=1,196,394           
Any major birth defect, n (%) 153 (3.2) 874 (3.4) 32117 (2.7) 
Neural tube defects*, n (%) <5** (<0.1)  10 (0.04) 287 (0.02) 
Orofacial clefts*, n (%) 8 (0.2) 55 (0.2) 2026 (0.2) 
Cardiac malformations*, n (%) 60 (1.2) 325 (1.3) 12201 (1.0) 
Gastrointestinal malformations*, n (%) 4 (0.1) 46 (0.2) 1080 (0.1) 
Limb reduction defects*, n (%) <5** (<0.1) 17 (0.1) 526 (0.04) 
Hypospadias*, n (%) 13 (0.3) 87 (0.3) 3363 (0.3) 
SC spontaneous conception 
*One child could have more than one birth defect  
**The exact numbers are not reported to ensure anonymity of the participants 
(Ginström Ernstad et al., AJOG, 2016) 
 
 





Birth defects occurred in 3.2% of singletons born after blastocyst transfer, in 3.4% 
of singletons born after cleavage stage transfer and in 2.7% of singletons in the 
general population. Following adjustment for relevant confounders listed in Table 7, 
the ORs for birth defects were not significant (AOR 0.94, 95% CI 0.79-1.13 versus 
cleavage stage and AOR 1.09, 95% CI 0.92-1.28 versus SC). In the crude analyses, 
when specific groups of birth defects were analyzed, the rate of neural tube defects 
was significantly higher after blastocyst transfer compared to SC (0.08% versus 
0.02%, OR 3.46; 95% CI 1.29-9.29). However, no adjustment could be done due to 
few events. 
 
Table 9. Birth defects (crude and adjusted ORs) for singleton pregnancies after blastocyst 
transfer (n=4819) versus cleavage stage transfer (n=25,747) and versus spontaneous 
conception (n=1,196,394). 




















Any birth defect 0.93 (0.78-1.11) 0.94 (0.79-1.13) 1.19 (1.01-1.40) 1.09 (0.92-1.28) 
Neural tube defects 2.14 (0.67-6.82) NA 3.46 (1.29-9.29) NA 
Orofacial clefts 0.78 (0.37-1.63) NA 0.98 (0.49-1.96) NA 
Cardiac malformations 0.99 (0.75-1.30) 0.99 (0.74-1.31) 1.22 (0.95-1.58) 1.16 (0.90-1.51) 
Gastrointestinal 
malformations 
0.46 (0.17-1.29) NA 0.92 (0.34-2.46) NA 
Limb reduction 
defects 
0.31 (0.04-2.36) NA 0.47 (0.07-3.36) NA 
Hypospadias 0.80 (0.45-1.43) NA 0.96 (0.56-1.66) NA 
OR odds ratio, CI confidence interval, SC spontaneous conception, NA no adjustment made 
because of few events reported  
                
*Adjusted ORs were obtained after stratification for year of birth of child, maternal age, parity, 
smoking, BMI, years of involuntary childlessness, child’s sex and, for comparison to cleavage 
stage, also for number of oocytes retrieved, number of embryos transferred and frozen/fresh 
embryo transfer 
                      
(Ginström Ernstad et al., AJOG, 2016)                         
 
Regarding other neonatal outcomes the rate of male gender was significantly higher 
and the rate of SGA significantly lower in the blastocyst group compared to both 
cleavage stage transfer and SC. Moreover, the singletons born following blastocyst 
transfer were more often born preterm (<37 weeks) and macrosomic compared to SC 
and the risk for perinatal mortality was higher compared to cleavage stage transfer.  
 
 





Maternal outcome      
Maternal outcomes are summarized in Table 10. The rate of placenta previa and 
placental abruption was significantly higher in singleton pregnancies after blastocyst 
transfer when compared both to singleton pregnancies after cleavage stage transfer 
and SC. The rate of PPH was higher in the blastocyst group compared to the SC 




Birth defects is an extremely important outcome after ART and following a previous 
Swedish study showing an increased risk of birth defects in children born after 
blastocyst transfer compared to cleavage stage transfer concerns were raised both 
among patients and IVF clinics (Kallen et al., 2010).  
 
The present study, including a much larger cohort of singletons born following 
blastocyst transfer, yet partly overlapping with the study by Källen et al., did not 
show any differences in the rate of birth defects when comparing blastocyst transfer 
to cleavage stage transfer. Neither were there any significant differences in 
subgroups of birth defects. Our results are in accordance with two meta-analysis 
including the same four observational studies with a total of 8737 singletons born 
following blastocyst transfer and 36,097 singletons following cleavage stage transfer 
and reporting on similar risks between the groups (Martins et al., 2017, Alviggi et 
al., 2018).  
 
The major strength in the present study is the inclusion of a complete national birth 
cohort of singletons born following blastocyst transfer and cleavage stage transfer 
during 2002-2013. Data were collected in the same way for all children and 
nationwide registers with high coverage rates were used. In addition, to minimize the 
risk of missing out on any diagnoses, birth defects recorded up to one year of age 
were included for analyses. However, data on birth defects leading to termination of 









Table 10. Neonatal and maternal outcomes (adjusted ORs) for singleton pregnancies after 
blastocyst transfer (n=4819) versus cleavage stage transfer (n=25,747) and versus 
spontaneous conception (n=1,196,394).                                                                                                  
Outcome Blastocyst vs                                
cleavage stage                             
Adjusted OR* (95% CI) 
Blastocyst vs SC                              
Adjusted OR* (95% CI) 
Male gender 1.10 (1.03-1.17) 1.06 (1.10-1.12) 
PTB <37 weeks 1.12 (0.99-1.27) 1.17 (1.05-1.31) 
LBW <2500 grams 
gramsgrams 
0.83 (0.71-0.97) 0.89 (0.77-1.04) 
SGA < -2 SD 0.71 (0.56-0.88) 0.70 (0.57-0.87) 
Macrosomia ≥4500 grams 1.16 (0.98-1.37) 1.24 (1.07-1.44) 
LGA > +2 SD 1.06 (0.91-1.23) 1.14 (0.997-1.31) 
Perinatal mortality 1.61 (1.14-2.29) 0.76 (0.57-1.02) 
 
Placenta previa 2.18 (1.79-2.65) 6.38 (5.31-7.66) 
Placental abruption 1.68 (1.20-2.35) 2.31 (1.70-3.13) 
Preeclampsia 1.00 (0.85-1.17) 1.02 (0.88-1.18) 
PPH 0.95 (0.84-1.08) 1.19 (1.07-1.33) 
Cesarean section 1.21 (1.13-1.31) 1.24 (1.16-1.33) 
 
OR odds ratio, CI confidence interval, SC spontaneous conception, PTB preterm birth <37 weeks, 
LBW low birth weight <2500 grams, SGA/LGA small/large for gestational age, SD standard 
deviation, PPH postpartum hemorrhage                    
Maternal outcomes included placenta previa (ICD 10 code O44), placental abruption (ICD 10 code 
O45), preeclampsia (ICD 10 code O14-O15), postpartum hemorrhage after vaginal delivery (ICD 10 
code O72; >1000mL)           
                                         
*Adjusted ORs were obtained after stratification for year of birth of child, maternal age, parity, 
smoking, BMI, years of involuntary childlessness, child's sex and for comparison to cleavage  




4.2 Paper II 
Neonatal and maternal outcome after frozen embryo transfer: 
Increased risks in programmed cycles. 
In total, 9726 singletons were born following FET, 24,365 following fresh transfer 
and 1,127,566 following SC in Sweden during 2005 to 2015. Of the singletons born 
following FET, 6297 were born following a natural cycle, 1983 following a 









Outcome following different cycle regimens in FET 
Maternal and neonatal outcomes following different cycle regimens in FET are 
summarized in Table 11 and 12. 
 
Table 11. Maternal and neonatal outcome in singleton pregnancies after frozen embryo 
transfer (natural, stimulated and programmed cycles) in Sweden 2005-2015 
Outcome All FET 
            
n=9726 









Placenta previa, n (%) 107 (1.1) 73 (1.2) 21 (1.1) 13 (0.9) 
Placental abruption, n (%) 44 (0.5) 29 (0.5) 8 (0.4) 7 (0.5) 
HDP, n (%) 663 (6.8) 381 (6.1) 130 (6.6) 152 (10.5) 
PPH, n (%) 943 (9.7) 497 (7.9) 165 (8.3) 281 (19.4) 
Cesarean section, n (%) 2719 (28.0) 1665 (26.4) 573 (28.9) 481 (33.3) 
Post term ≥42 weeks, n (%) 584 (6.0) 363 (5.8) 93 (4.7) 128 (8.9) 
PTB <37 weeks, n (%) 592 (6.1) 377 (6.0) 117 (5.9) 98 (6.8) 
LBW <2500 grams, n (%) 346 (3.6) 222 (3.5) 76 (3.8) 48 (3.3) 
SGA < -2 SD, n (%) 271 (2.8) 179 (2.8) 54 (2,7) 39 (2.7) 
Macrosomia ≥4500 grams, n (%) 503 (5.2) 292 (4.6) 104 (5.2) 107 (7.4) 
LGA > +2 SD, n (%) 637 (6.5) 386 (6.1) 139 (7.0) 112 (7.8) 
Major birth defects, n (%) 370 (3.8) 242 (3.8) 92 (4.6) 67 (4.6) 
FET frozen embryo transfer, HDP hypertensive disorders in pregnancy, PPH postpartum  
hemorrhage, PTB preterm birth <37 weeks, LBW low birth weight <2500 grams,                   
SGA/LGA small/large for gestational age, SD standard deviation                                       
Maternal outcomes included placenta previa (ICD 10 code O44), placental abruption (ICD 10 code 
O45), hypertensive disorders in pregnancy (ICD 10 code O13-O15) and postpartum hemorrhage after 
vaginal delivery (ICD 10 code O72; >1000mL)                         
Major birth defects according to EUROCAT (www.eurocat-network.eu)                                
(Ginström Ernstad et al., AJOG, 2019) 
 
For maternal outcomes, the rate of HDP and PPH differed in the groups. HDP 
occurred in 6.1% of women following a natural cycle, in 6.6% following a stimulated 
cycle and in 10.5% following a programmed cycle. When comparing programmed 
cycles to natural and stimulated cycles, the risk was significantly higher in the 
programmed cycles both compared to natural cycles and stimulated cycles following 
adjustment for several confounders including PCOS (listed in Table 7) (AOR 1.78, 
95% CI 1.43-2.21 and AOR 1.61, 95% CI 1.22-2.10, respectively).  
  
 





Table 12. Maternal and neonatal outcomes (adjusted ORs) for singleton pregnancies after 
stimulated (n=1983) versus natural cycles (n=6297 natural cycles) in frozen embryo transfer, 
programmed (n=1446) versus natural cycles (n=6297) in frozen embryo transfer and 
programmed (n=1446) versus stimulated cycles (n=1983) in frozen embryo transfer. 
Outcome Stimulated vs  
natural cycles  
Adjusted* OR    
(95% CI) 
Programmed vs 
natural cycles  
Adjusted* OR      
(95% CI) 
Programmed vs 
stimulated cycles  
Adjusted* OR           
(95% CI) 
Placenta previa 0.82 (0.50-1.36) 0.71 (0.36-1.37) 1.00 (0.46-2.16) 
Placental abruption 0.75 (0.32-1.76) 0.93 (0.37-2.35) 0.56 (0.16-1.99) 
HDP 1.05 (0.84-1.31) 1.78 (1.43-2.21) 1.61 (1.22-2.10) 
PPH 1.05 (0.86-1.28) 2.63 (2.20-3.13) 2.87 (2.29-3.60) 
Cesarean section 1.15 (1.01-1.30) 1.39 (1.21-1.60) 1.27 (1.08-1.50) 
Post term ≥42 weeks 0.87 (0.68-1.11) 1.59 (1.27-2.01) 1.98 (1.47-2.68) 
PTB < 37 weeks 0.94 (0.74-1.19) 1.09 (0.85-1.40) 1.15 (0.84-1.57) 
LBW < 2500 grams 1.04 (0.77-1.40) 0.88 (0.62-1.26) 0.83 (0.55-1.27) 
SGA < -2 SD 1.06 (0.76-1.47) 0.91 (0.62-1.35) 0.89 (0.56-1.43) 
Macrosomia ≥ 4500 grams 1.14 (0.89-1.46) 1.62 (1.26-2.09) 1.40 (1.03-1.90) 
LGA > +2 SD 1.11 (0.89-1.38) 1.27 (0.99-1.61) 1.10 (0.82-1.47) 
Major birth defects 1.03 (0.79-1.33) 0.999 (0.74-1.34) 0.94 (0.66-1.34) 
OR odds ratio, CI confidence interval, HDP hypertensive disorders in pregnancy,  
PPH postpartum hemorrhage, PTB preterm birth <37 weeks, LBW low birth  
weight <2500 grams, SGA/LGA small/large for gestational age, SD standard deviation 
Maternal outcomes included placenta previa (ICD 10 code O44), placental abruption (ICD 10 code 
O45), hypertensive disorders in pregnancy (ICD 10 codes O13-O15) and postpartum hemorrhage after 
vaginal delivery (ICD 10 code O72; >1000mL)                                                                  
*Adjusted ORs were obtained after stratification for maternal age, BMI, parity, year of birth of child, 
smoking, chronic hypertension, child´s sex, level of maternal education, years of involuntary 
childlessness, cause of infertility, IVF/ICSI, freezing method (vitrification or slow-freeze), culture 
duration and number of gestational sacs                       
Major birth defects according to EUROCAT (www.eurocat-network.eu)                      
(Ginström Ernstad et al., AJOG, 2019) 
 
Regarding PPH, an increase in risk was also seen in programmed cycles in 
comparison to natural cycles (AOR 2.63, 95% CI 2.20-3.13) as well as in comparison 
to stimulated cycles (AOR of 2.87, 95% CI 2.29-3.60) with a risk of almost 20% 
among programmed cycles. For placenta previa and placental abruption, we report 
on no significant differences in regards of cycle regimen used with absolute risks of 
around 1% for placenta previa and around 0.5% for placental abruption in all three 
groups. 
 





For neonatal outcomes, the rate of post term birth was significantly higher following 
programmed cycles in comparison to natural cycles (AOR 1.59, 95% CI 1.27-2.01)  
as well as in comparison to stimulated cycles (AOR 1.98, 95% CI 1.47-2.68). 
Moreover, programmed cycles had a higher risk of macrosomia in comparison to 
both natural and stimulated cycles (AOR 1.62, 95% CI 1.26-2.09 and AOR 1.40, 
95% CI 1.03-1.90, respectively). No significant differences were seen for PTB, 
LBW, perinatal mortality or major birth defects.  
 
Outcome following FET in comparison to fresh transfer and SC 
In comparison to fresh transfer, FET was associated with increased risks of HDP and 
PPH (1.5-1.6) but decreased risks of placenta previa and placental abruption (AOR 
0.4-0.6) in comparison to fresh IVF. In comparison to SC, FET was associated with 
increased risks of placenta previa, HDP and PPH (AOR 1.2-1.8) whereas the risk of 
placental abruption did not significantly differ between the groups.   
 
For neonatal outcomes, FET was associated with a 1.6-1.9-folded increase for post 
term birth, macrosomia and LGA whereas the risk estimates for PTB, LBW and SGA 
were lower (AOR 0.6-0.8) in the adjusted analyses. When comparing FET to SC, the 
rate of macrosomia and LGA was increased 1.6-folded whereas the rate of LBW and 




We conclude that pregnancies following programmed cycles are more prone to HDP, 
PPH, post term birth and macrosomia as opposed to natural and stimulated cycles. 
Preeclampsia is a multisystem disorder with poorly understood etiology and 
pathophysiology. Since delivery is the only cure for the disorder, the placenta is 
considered to play a crucial role. Interestingly, four recently published studies reveal 
an association between the absence of CL in programmed cycles and HDP (von 
Versen-Hoynck et al., 2019, von Versen-Hoynck et al., 2019, von Versen-Hoynck 
et al., 2019, von Versen-Hoynck et al., 2020). The CL, lacking in programmed cycles 
due to suppression of the pituitary-ovarian hormonal axis, is the sole source of relaxin 
in early pregnancy. Subsequently, the lack of relaxin but also other, yet unidentified 
vasodilators from the CL, could have physiologic importance altering the vascular 
adaptation in early pregnancy and potentially inhibit the drop in mean arterial 
 





pressure thereby causing HDP during the second half of the pregnancy. Our study 
support these findings.  
 
In addition, in our study we saw a 3-folded risk of PPH following programmed cycles 
in comparison to natural and stimulated cycles. Several risk factors for PPH exist 
including large babies, more common in programmed cycles. Moreover, the 
increased risk of post term birth and HDP in programmed cycles might increase the 
rate of labor induction, also a risk factor for PPH. In conclusion, the increased risk 
of PPH in programmed cycles could at least partly be explained by other risks 
associated with the cycle regimen.   
 
Since information on medication used for IVF treatment is lacking in the Q-IVF, 
information on medication used for stimulation was collected through the Prescribed 
Drug Register. All medication purchased 70 days prior to embryo transfer was 
assumed to belong to the analyzed treatment cycle which is considered the main 
limitation in this study. Programmed cycles have gained in popularity mainly due to 
decreased demand on extensive monitoring and the possibility to schedule transfers 
to weekdays. However, owing to the increased risks in programmed cycles, this cycle 
regimen should only be performed when ovulation fails. In our study we were able 
to adjust for several relevant confounders including chronic hypertension and cause 
of infertility.  
 
4.3 Paper III 
Perinatal and maternal outcome after vitrification of blastocysts: a 
Nordic study in singletons from the CoNARTaS group.  
In this register-based study on Swedish and Danish data covering the years 2002 to 
2015 we had 3650 singletons born following transfer of vitrified blastocysts, 8123 
singletons born following transfer of slow-frozen cleavage stage transfers and 4469 
singletons born following transfer of fresh blastocysts. The majority of children, 
13,991 (86.1%), were born in Sweden.  
Neonatal and maternal outcomes are summarized in Table 13 and 14. For PPH only 
Swedish data were analyzed due to the differences in definition. In Sweden, PPH is 









Outcome following different freezing techniques 
Following transfer of a vitrified blastocyst, 7.4% of singletons were born preterm. 
For the slow-frozen cleavage stage group the estimate was 6.3% and for the fresh 
blastocyst group 8.9%. After adjustment for relevant confounders, the rate of PTB 
was significantly higher following transfer of vitrified blastocysts in comparison to 
slow-frozen cleavage stage transfer (AOR 1.33, 95% CI 1.09-1.62). No other 
significant differences for neonatal and maternal outcome could be found when 
comparing the two groups.  
 
Table 13. Perinatal and maternal outcome in singleton pregnancies after vitrified blastocyst 
transfer (n=3650) compared with slow-frozen cleavage stage transfer (n=8123) and fresh 
blastocyst transfer (n=4469), 2002-2015. 
Outcome Vitrified       
blastocysts    
                
n=3650 
Slow-frozen     
cleavage stage 
transfer                       
n=8123 
Fresh                      
blastocysts 
                   
n=4469 
Post term ≥42 weeks, n (%) 281 (7.7) 620 (7.6) 190 (4.3) 
PTB <37 weeks, n (%) 271 (7.4) 513 (6.3) 398 (8.9) 
LBW <2500 grams, n (%) 127 (3.5) 304 (3.8) 256 (5.7) 
Macrosomia ≥4500g, n (%) 183 (5.0) 410 (5.1) 117 (2.6) 
SGA < -2 SD, n (%) 92 (2.5) 233 (2.9) 198 (4.4) 
LGA > +2 SD, n (%) 247 (6.8) 513 (6.3) 181 (4.1) 
Birth defects, any, n (%) 152 (4.2) 338 (4.2) 217 (4.9) 
Placenta previa, n (%) 58 (1.6) 82 (1.0) 182 (4.1) 
Placental abruption, n (%) 20 (0.5) 42 (0.5) 49 (1.1) 
HDP, n (%) 258 (7.1) 534 (6.6) 231 (5.2) 
PPH*, n (%) 362 (10.1) 645 (9.4) 231 (6.6) 
Cesarean section, n (%)  1078 (29.6) 2205 (27.1)  1205 (27.0) 
PTB preterm birth <37 weeks, LBW low birth weight <2500 grams, SGA/LGA           
small/large for gestational age, SD standard deviation, HDP hypertensive disorders                
in pregnancy, PPH postpartum hemorrhage 
Birth defects were defined according to ICD 10 codes beginning with Q with no  
exclusion for minor defects                                                
Maternal outcomes included placenta previa (ICD 10 code O44), placental abruption  
(ICD 10 code O45), hypertensive disorders in pregnancy (ICD 10 codes O13-O15) and postpartum 
hemorrhage after vaginal delivery (ICD 10 code O72; >1000mL).                              
*Only Swedish data                           









Outcome following transfer of frozen vs fresh blastocysts  
Transfer of frozen blastocysts was associated with an increased risk of larger babies 
with a 1.5 and 1.8-folded risk for LGA and macrosomia, respectively, and a 40% 
decrease in risk for both LBW and SGA in comparison to fresh blastocyst transfer, 
results that are in accordance with paper II for comparisons between fresh and frozen 
transfers. Regarding maternal outcomes, the rate of HDP (AOR 1.47, 95% CI 1.19-
1.81) and PPH (AOR 1.68, 95% CI 1.39-2.03) were significantly higher and the rate 
of placenta previa significantly lower (AOR 0.35, 95% CI 0.25-0.48) following 




In this study we aimed at investigating whether the introduction of vitrification poses 
any risks for the children and their mothers when compared to slow-freezing. Using 
the CoNARTaS cohort, we included all singletons born following transfer of vitrified 
blastocysts, slow-frozen cleavage stage embryos and fresh blastocysts during 2002-
2015 in Sweden and Denmark yielding a reasonable large sample size. Since the new 
freezing technique, vitrification, has improved success rates in terms of implantation 
and pregnancy rates particularly for blastocysts (Stehlik et al., 2005), a comparison 
of vitrified and slow-frozen blastocysts was not feasible. 
 
The risk of PTB was slightly higher following transfer of vitrified blastocysts 
compared to slow-frozen cleavage stage transfer, a finding that might be attributable 
to the extended culture more than to the freezing technique as meta-analyses has 
shown an increased risk of PTB in blastocyst compared to cleavage stage transfers 
(Dar et al., 2014, Martins et al., 2017, Alviggi et al., 2018). No other differences in 
outcomes were seen, indicating that the freezing technique per se does not seem to 
influence the neonatal or maternal outcome. At date, neither have other studies 
observed a difference in neonatal or maternal outcomes following the introduction 
of vitrification when compared to slow-freezing of blastocysts (Li et al., 2014) or 
cleavage stage embryos (Kaartinen et al., 2016, Gu et al., 2019).  
 
The major drawback in this study is the comparison of vitrified blastocysts and slow-
frozen cleavage stage embryos. However, since vitrification was introduced 
simultaneously with blastocyst transfer in Sweden and Denmark, it was not possible 
to explore the effect of vitrification per se in this study. Even though there are some 
children born after transfer of vitrified cleavage stage embryos, the number was too 
 





small for statistical comparison. 
 
Table 14. Adjusted odds ratios of perinatal and maternal outcome in singleton deliveries after 
vitrified blastocyst transfer (n=3650) compared with slow-frozen cleavage stage transfer 
(n=8123) and fresh blastocyst transfer (n=4469), 2002-2015 
Outcome Vitrified blastocyst vs                     
slow-frozen cleavage 
stage transfer   
Adjusted OR* (95% CI) 
Vitrified vs                                 
fresh blastocyst      
transfer 
Adjusted OR* (95% CI) 
Post term birth ≥42 weeks 1.01 (0.85-1.20) 1.61 (1.31-1.98) 
PTB <37 weeks 1.33 (1.09-1.62) 0.86 (0.71-1.04) 
LBW <2500 grams 0.91 (0.70-1.19) 0.57 (0.44-0.74) 
SGA < -2 SD 0.85 (0.63-1.13) 0.58 (0.44-0.78) 
Macrosomia ≥4500 grams 0.93 (0.76-1.15) 1.77 (1.35-2.31) 
LGA > +2 SD 1.10 (0.91-1.32) 1.48 (1.18-1.84) 
Birth defects, any 1.16 (0.91-1.47) 0.99 (0.77-1.27) 
Placenta previa 1.48 (0.98-2.24) 0.35 (0.25-0.48) 
Placental abruption 1.78 (0.93-3.40) 0.65 (0.37-1.16) 
HDP 0.97 (0.81-1.17) 1.47 (1.19-1.81) 
PPH** 1.03 (0.88-1.25) 1.68 (1.39-2.03) 
Cesarean section 1.17 (1.05-1.30) 1.15 (1.03-1.29) 
OR odds ratio, CI confidence interval, PTB preterm birth <37 weeks, LBW low birth         
weight <2500 grams, SGA/LGA small/large for gestational age, SD standard deviation,      
HDP hypertensive disorders in pregnancy, PPH postpartum hemorrhage 
Birth defects were defined according to ICD 10 codes beginning with Q with no exclusion      
for minor defects.                 
Maternal outcomes included placenta previa (ICD 10 code O44), placental abruption  
(ICD 10 code O45), hypertensive disorders in pregnancy (ICD 10 codes O13-O15) and postpartum 
hemorrhage after vaginal delivery (ICD 10 code O72; >1000mL)  
*Adjusted for country of birth of child, year of birth of child, maternal age, BMI, parity, smoking, 
parental educational level, fertilization method (IVF/ICSI), single embryo transfer, number of 
gestational sacs and child´s sex                     
**Only Swedish data 









4.4  Paper IV 
Perinatal, maternal and early childhood outcome following 
preimplantation genetic testing: a national register-based study 
This study included singletons born following PGT in Sweden (n=267) since the 
birth of the first child and as far as information was available, i.e. 1996-2017. The 
PGT children were compared to two control groups:  
 
I. All IVF/ICSI singletons (n=55,355) born in Sweden during 1996-2017. 
 
II. Matched control group of singletons born following SC (n=26,535) during 1996-
2017. The SC controls were matched for year of birth of child, maternal age +/- 5 
years, parity and for delivery hospital or nearest delivery hospital. We aimed for 100 
controls per PGT child. However, in five cases, we did not find 100 matched controls, 
these cases had 41, 64, 66, 68 and 96 controls each.  
 
The majority of PGT treatments were performed for monogenic disorders (65.2%). 
More details are presented in the Results section in paper IV.  
 
 
Neonatal and maternal outcome 
When comparing PGT pregnancies to IVF/ICSI pregnancies there were no 
significant differences for PTB and LBW. Regarding maternal outcomes, the rates 
of HDP, placenta previa and PPH were comparable between the groups. The AORs 
are presented in paper IV.  
 
When comparing PGT to spontaneously conceived singletons, significantly higher 
risks for PTB and LBW were found. For maternal outcomes, the rate of placenta 
previa was significantly higher following PGT. Regarding HDP and PPH, there were 
no significant differences. The AORs are presented in paper IV.  
 
 
Early childhood outcome 
The mean follow-up time was 3.3 years for PGT offspring and the matched 
spontaneous controls. For IVF/ICSI offspring, the follow-up time was twice as long, 
7.7 years. Data on early childhood outcome were collected from the Swedish NPR 
covering in- and outpatient care, yet not primary care. 
 





Complete data on early childhood outcome is presented in paper IV. Shortly, in the 
crude analysis the risk of sepsis was significantly higher in PGT singletons compared 
to both IVF/ICSI and spontaneous singletons. However, the analysis is based on few 
cases in the PGT group, no adjustment was made and the results should thus be taken 




Our study shows that neonatal and maternal outcomes following PGT are 
comparable to pregnancies following IVF/ICSI yet, there are higher risks in 
comparison to SC, in line with other IVF/ICSI pregnancies. Data on early childhood 
health in PGT singletons are sparse, yet reassuring compared to singletons conceived 
through IVF/ICSI and spontaneously conceived singletons. However, a drawback is 
the short follow-up time.  
 
Two control groups were set up for this study. The first group consisted of all 
IVF/ICSI singleton pregnancies. The comparison between PGT and IVF/ICSI 
pregnancies gave us the possibility to study the effect of the embryo biopsy per se 
on the outcome. The second control group consisted of matched spontaneous controls 
from the Swedish MBR. The main reason for using matched controls instead of the 
entire spontaneous population in the MBR, was that we did not plan to do additional 
analysis or sub analyses that would have been affected by the matching. One hundred 
matched controls for each case can be considered sufficient in terms of 
generalizability. The matching variables chosen, year of birth of child, maternal age, 
parity and delivery hospital, were chosen to balance the groups for important 
predictors of outcome.  
 
Since the proportion of children born following PGT increased throughout the study 
period, the majority of children were born later in the study period. The short follow-
up time for all children but particularly for the PGT children and their matched 
spontaneous controls is the major drawback in the study considering early childhood 
outcome. For example, children with a mild case of cerebral palsy might not get the 
diagnosis until the age of four years. However, data on early childhood outcomes 
were collected using national health registers and the data was collected in the same 
way for all three groups. There are no previous studies published investigating the 
early childhood outcome for PGT children concerning somatic and psychiatric 
diseases. The few earlier studies on growth, neurological development, body 
 





composition and blood pressure (Desmyttere et al., 2009, Belva et al., 2018, Kuiper 
et al., 2018) all suffer from small sample sizes and methodological problems such as 










The goal of this thesis was to evaluate the outcome for the children born through 
ART and the mothers undergoing ART following advanced techniques. The 
increased demand on ART, with up to 7.1% of national birth cohorts in Europe being 
ART children (de Geyter et al., 2020), necessitates follow-up of both the children 
and their mothers. The results are in general reassuring even though some differences 
exist both between different techniques but also as opposed to SC.  
 
5.1 Neonatal outcome following advanced techniques in ART 
Singletons born following ART treatment are more often born preterm, with LBW 
and they also have a slightly increased risk of birth defects in comparison to 
spontaneously conceived singletons (Helmerhorst et al., 2004, Jackson et al., 2004, 
McDonald et al., 2009, Pandey et al., 2012, Hansen et al., 2013, Qin et al., 2017, 
Zhao et al., 2020). However, the risks associated with ART has decreased markedly 
during the last decades as discussed in chapter 1.9. Due to the increased use of 
extended culture and FET including vitrification as well as PGT we ought to study 
the neonatal outcome following these advanced techniques. 
 
 
Blastocyst transfer and birth defects 
Following the introduction of blastocyst transfer, concerns were raised whether this 
technique increase the rate of birth defects among the newborns. In 2010, a Swedish 
register-based study on 1311 children born after blastocyst transfer revealed a 
significantly higher risk in blastocyst offspring compared to offspring born following 
cleavage stage transfer (Kallen et al., 2010). A Canadian retrospective study 
(n=3206) did, however, not reveal any differences (Dar et al., 2013) and these two 
studies have then been summarized in a meta-analysis showing an increased risk 
following blastocyst transfer, mainly driven by the results in the Swedish study (Dar 
et al., 2014). Finally, two more recent meta-analyses including the same four studies, 
one of them being our study, reported on similar risks of birth defects following 
transfer with blastocysts and cleavage stage embryos (Martins et al., 2016, Alviggi 
et al., 2018). In our study, we found similar risks for birth defects following 
blastocyst transfer as opposed to cleavage stage transfer, divergent to the results in 
the previous Swedish study, yet in accordance with the study by Dar et al. (2013) 
 





and the meta-analyses. There are some possible explanations behind these divergent 
results. In the Swedish study by Källen et al., partly covering the same cohort as our 
study, both singletons and multiples (236 multiples out of 1311 children, 18%) were 
included, potentially causing a bias in consideration of the almost doubled risk of 
birth defects in multiples as opposed to singletons (Li et al., 2003, Glinianaia et al., 
2008, Zhang et al., 2011). Moreover, our study was almost five times larger in 
regards of singletons. In the study by Källen et al., the absolute risk for a relatively 
severe birth defect was 4.7% in the blastocyst group and 4.1% in the cleavage stage 
group whereas the corresponding numbers in our study were 3.2% and 3.4%, 
respectively. In the Canadian study on singletons, the main limitation was the way 
of data collection. The information on major and minor birth defects were collected 
directly via the parents, either by telephone or by mail, not through medical records, 
a possible explanation to the somewhat lower absolute risks (2.4% following transfer 
of a day 5-6 embryo and 2.3% following transfer of a day 2-3 embryo) in comparison 
to our study. In our study, the follow-up time for birth defects was up to one year of 
age whereas the follow-up time in the study by Källen et al. and Dar et al. is not 
stated. When comparing blastocyst transfer to SC, neither was any significant 
differences for birth defects found in our study (3.2% in the blastocyst group and 
2.7% in the SC group), possibly due to a relatively small sample size.  
 
Yet, for specific birth defects, previous studies have shown that there might be an 
association between ART and some specific birth defects such as neural tube defects, 
gastrointestinal and cardiac malformations (Kallen et al., 2005, Chen et al., 2018, 
Giorgione et al., 2018). In embryonal development, blastogenesis occurs during the 
first four weeks, followed by the organogenesis. Some defects, sometimes called the 
blastogenesis defects, occur during the first four weeks and involves neural tube 
defects, abdominal wall defects as well as esophageal and anal atresia. ART 
treatment, manipulating with the embryo at an early developmental stage, could thus 
be hypothesized to be associated with the blastogenesis defects as shown in an 
Australian study (Halliday et al., 2010).  
 
 
Blastocyst transfer and neonatal outcome 
Regarding being born preterm, we found similar rates for PTB when comparing 
blastocyst to cleavage stage transfer, yet higher risks when compared to SC. However, 
the lower CI for PTB, when comparing blastocyst and cleavage stage transfer, was 
close to one (95% CI 0.99-1.27). Recent meta-analyses consistently show a higher risk 
 





of PTB following extended culture compared to day 2-3 transfers (Dar et al., 2014, 
Martins et al., 2016, Alviggi et al., 2018). In the meta-analysis by Alviggi et al, the 
results were, however, only seen in fresh and fresh plus frozen cycles but not in frozen 
cycles alone. In the other meta-analyses these cycles were lumped together. In our 
study on blastocyst transfer, including both fresh and frozen cycles, the absolute risk 
was 7.8% in fresh and 6.5% in frozen cycles, yet no statistical comparisons were made 
for frozen blastocyst versus frozen day 2-3 transfer or fresh blastocyst versus fresh day 
2-3 transfer. The results in our study, pointing in the same direction as the meta-
analyses, however, not reaching a significant level, could be attributable to the study 
size/power. Additionally, the PTB rate varies in different ethnicities with relatively 
low rates in white populations, e.g. the Nordic countries.  
 
Extended culture has been shown to influence birth weight, with possibly larger 
babies as compared to cleavage stage transfer. In our study, when analyzing fresh 
and frozen cycles together, we found a higher risk of LGA in the crude analysis 
between blastocyst and cleavage stage transfer, however, following adjustment for 
confounders including fresh or frozen transfer, this difference disappeared. Even 
though the rate of LGA in the adjusted analysis was similar there were other 
indications that extended culture might influence birth weight. The rate of 
macrosomia was higher in comparison to SC, the risk of LBW was lower in 
comparison to day 2-3 transfer and the risk of SGA lower both in comparison to day 
2-3 transfer and SC. In another study, there were neither any differences regarding 
LGA found in 4000 singletons born following blastocyst transfer adjusting for 
relevant confounders including fresh or frozen cycle (Fernando et al., 2012) while 
two studies in fresh cycles observed an increase in LGA and a higher mean birth 
weight following blastocyst transfer (Makinen et al., 2013, Zhu et al., 2014). In 
accordance with our study, a lower risk of SGA has also been observed in other 
studies when comparing day 5-6 transfer and day 2-3 transfer (Maheshwari et al., 
2013, Ishihara et al., 2014). Animal studies have shown increased risk for 
intrauterine overgrowth, called the large offspring syndrome, in cattle and sheep 
cultured in vitro to the blastocyst stage (Young et al., 1998). However, the large 
offspring syndrome in animals is associated with organ anomalies, findings that are 
not in line with our study showing similar risks for birth defects following extended 
culture in comparison to day 2-3 transfers.  
 
According to a recent study, based on WHO data, there are 106 males born for each 
100 females (Grech and Mamo, 2019), very close to the male-female ratio seen in the 
spontaneously conceived children in our studies. In IVF, extended culture has been 
 





shown to skew the ratio in favor for male (Luna et al., 2007, Chang et al., 2009, Dean 
et al., 2010, Maalouf et al., 2014, Ding et al., 2018, Hattori et al., 2019). Likewise, in 
our study on blastocyst transfer, we found an altered male/female ratio both in 
comparison to cleavage stage transfer and SC with almost 53% male offspring 
following blastocyst transfer corresponding to 112 males for each 100 females. A 
possible explanation is faster cleavage in embryos of male origin causing a selection 
of male embryos for transfer at the blastocyst stage (Tarín et al., 1995, Ménézo et al., 
1999, Alfarawati et al., 2011). Another explanation might be a higher post-
implantation fetal demise in female embryos following blastocyst transfer (Tarín et 
al., 2014).  
 
 
Frozen embryo transfer and neonatal outcome 
In recent years, there has been emerging evidence that FET is associated with larger 
babies. In our studies on frozen transfers, paper II and III, the risk of LGA and 
macrosomia was increased 1.5-1.9-folded compared to fresh transfer but also 
compared to SC. Our findings of larger babies following FET are supported by 
several previous studies (Wennerholm et al., 2013, Pinborg et al., 2014, Maheshwari 
et al., 2018, Berntsen et al., 2019) as well as a sibling study (Henningsen et al., 2011). 
In such a study, the outcome is compared in siblings born to the same mother with 
one sibling born following SC and another following ART or one sibling born 
following one ART technique and another following another ART technique. The 
Danish sibling study, published in 2011, showed significantly higher birth weights 
in siblings born following FET than for those born following fresh IVF, indicating 
that the cryo technique may induce changes in embryo development and intrauterine 
growth (Henningsen et al., 2011).  
 
FET seems to be associated with an elevated risk of post term rather than preterm 
birth (Wikland et al., 2010, Wennerholm et al., 2013). In our studies on frozen 
transfers (paper II and III), we report on a 1.6-folded increase for post term birth in 
comparison to fresh transfer. The definition of post term birth is a pregnancy lasting 
for more than ≥294 days, i.e. ≥42 weeks and has been shown to be associated with 
an increase in perinatal mortality (Ingemarsson and Källén, 1997, Smith, 2001, 
Nakling and Backe, 2006, Wennerholm et al., 2019). At date, in Sweden, induction 
is recommended at 42+0 weeks at the latest whereas in Denmark, induction is 
recommended at 41+2-41+6 weeks. Gestational age for SC pregnancies is 
determined from the 1st or 2nd trimester ultrasound or from the first day of the last 
 





menstrual period if information on the ultrasound is unavailable. In IVF pregnancies 
gestational age is rather calculated from the day of embryo transfer and culture 
duration. Whether the accuracy of these two calculations of gestation age differ is 
not fully known but with today’s knowledge, calculating gestational age in ART 
pregnancies should be based on fertilization date, i.e. day of embryo transfer and 
culture duration (Butt et al., 2014).  
 
Altogether, for both blastocyst transfer and FET, the findings of larger babies could 
be due to selection of good quality embryos surviving extended culture and 
freezing/thawing. On the other hand, poor embryo quality has not been shown to be 
associated with adverse neonatal and maternal outcome in two smaller studies (Oron 
et al., 2014, Akamine et al., 2018). Moreover, possible epigenetic changes and 
differences in culture conditions including different culture medias and variations in 
oxygen concentrations might matter (Dumoulin et al., 2010, Gardner, 2016, Mani 
and Mainigi, 2018). In addition, parental characteristics might influence the outcome 
and thus need to be adjusted for. Regarding larger babies and FET, one hypothesis is 
that in vitro culture is prone to intrauterine overgrowth (Young et al., 1998, Grace 
and Sinclair, 2009) but that changes in steroid profile following the stimulation used 
in fresh cycles out rules these overgrowing tendencies. It is also important to keep in 
mind that the divergent results seen in studies could be explained by differences in 




Frozen embryo transfer: Freezing techniques and neonatal outcome 
When investigating the effect of freezing techniques on gestational age, we think that 
the increased risk of PTB following transfer of vitrified blastocysts shown in paper 
III (AOR 1.33, 95% CI 1.09–1.62) might be attributable to the extended culture rather 
than to the vitrification owing to the fact that blastocyst transfer seems to be 
associated with PTB as discussed before. Few studies have investigated the effect of 
freezing technique on outcome. In a Finnish study, no differences in the rate of PTB 
were seen in 276 children, both singletons and multiples, born following transfer of 
cleavage stage embryos that were vitrified or slow-frozen (Kaartinen et al., 2016). 
Neither were any differences in neonatal outcome seen in a larger study on 4721 
vitrified blastocyst and 1965 slow-frozen blastocysts in singleton pregnancies (Li et 
al., 2014) nor in a later study on 297 pairs of newborns born following vitrified or 
slow-frozen day 3 embryos (Gu et al., 2019). Regarding our study, a comparison 
 





between vitrification and slow-freeze in blastocysts would have been more 
appropriate than the comparison we did. Since vitrification of blastocysts have been 
shown to be much more successful than slow-frozen blastocysts, increasing both 
survival-, implantation- and pregnancy rates (Stehlik et al., 2005), such a study is, 
however, hardly feasible, at least not in the Nordic countries.  
 
 
Frozen embryo transfer and birth defects 
There were no differences in the rate of birth defects between different cycles 
regimens (paper II), neither did the freezing technique seem to influence the rate of 
birth defects (paper III). Likewise, when comparing frozen and fresh embryo 
transfer, similar risks were detected (paper II and III). These results are in line with 
several other studies showing similar rates for birth defects in fresh and frozen cycles 
(Pelkonen et al., 2014, Maheshwari et al., 2018). 
 
 
Preimplantation genetic testing and neonatal outcome 
In comparison to singletons born following IVF/ICSI, PGT singletons had 
comparable outcomes in terms of PTB, LBW and birth defects, results that are in line 
with previous studies (Liebaers et al., 2010, Desmyttere et al., 2012, Hasson et al., 
2017, Sunkara et al., 2017, He et al., 2019, Zhang et al., 2019). At date, there are no 
indications that the invasiveness of the technique used in PGT have detrimental 
effects on the neonatal outcome.  
 
 
In summary, extended culture might be associated with a higher risk of PTB whereas 
FET seems to reduce the risk, yet increase the risk of post term birth, especially in 
programmed cycles. Singletons born following FET are more prone to macrosomia 
and LGA both in comparison to fresh transfer and SC and blastocyst transfer might 
be associated with larger babies. The freezing technique or the embryo biopsy used 
in PGT does not seem to alter the neonatal outcome.  
 
5.2  Maternal outcome following advanced techniques in ART 
In general, placental complications including HDP seems to be more common in ART 
pregnancies compared to spontaneous pregnancies (Pandey et al., 2012, Opdahl et al., 
 





2015, Qin et al., 2016, Vermey et al., 2019) and for placenta previa the risk has 
increased over time in ART pregnancies (Petersen et al., 2020). Also, in a Norwegian 
sibling study there was a 3-folded increased rate of placenta previa in ART 
pregnancies as opposed to SC pregnancies within the same mother, indicating that 
the ART technique per se may play a role (Romundstad et al., 2006). 
 
 
Blastocyst transfer: placenta previa and placental abruption 
Following blastocyst transfer, we found a two-folded risk of placenta previa in 
comparison to cleavage stage transfer and a 6-folded risk in comparison to SC. When 
comparing transfer of blastocysts to day 2-3 embryos, one recent study revealed a 
higher risk of placenta previa following blastocyst transfer (Spangmose et al., 2019) 
while other studies showed no differences (Fernando et al., 2012, Ishihara et al., 
2014). The study by Spangmose et al., covering the years of 2002-2015 for Swedish 
data, partially overlaps with the study cohort used in our study (paper I), however, 
only including fresh cycles. In the Australian study (Fernando et al., 2012), 70% of 
transfers were performed in a fresh cycle and adjustment made for cycle type. In the 
Japanese study (Ishihara et al., 2014) the vast majority of blastocyst transfers were 
performed in frozen cycles and revealed no association between extended culture or 
FET and placenta previa. In our study, 37% of blastocyst transfers were performed 
in frozen cycles and adjustment was made for fresh or frozen transfer. Interestingly, 
two studies, including both day 2-3 and day 5-6 embryos, have shown a potentially 
protective effect of FET on placenta previa (Sazonova et al., 2012, Sha et al., 2018). 
A previous Australian study suggested an association between endometrial thickness 
>9 mm and placenta previa (Rombauts et al., 2014). One could hypothesize that 
extended culture and the stimulation in fresh cycles causes a thicker lining in the 
uterine cavity, thus predisposing to placenta previa. Besides different distributions 
of fresh and frozen transfers, the reasons for the divergent results between the studies 
mentioned are probably many. First, the diagnostic criteria may vary. Today there 
are different criteria for diagnosis (complete/partial/marginal placenta previa and 
low-lying placenta) and the diagnosis is also dependent on frequency of surveillance 
during pregnancy, e.g.  a possibly closer surveillance of ART pregnancies could 
contribute to the differences. Moreover, there might also be differences in 
registration practices, e.g. at what time during pregnancy the diagnosis of placenta 
previa is recorded. Second, the reason for infertility might matter. Endometriosis, 
independently of ART treatment, has been shown to be associated with placenta 
previa (Rombauts et al., 2014). In addition, advanced maternal age, multiparity, 
 





smoking, male fetuses, multiple pregnancies, prior cesarean delivery as well as 
spontaneous and induced abortions might contribute to the incidence of placenta 
previa (Faiz and Ananth, 2003, Karami et al., 2018). Noteworthy, according to a 
recently published CoNARTaS study, the risk for placenta previa has increased 
substantially in ART pregnancies for the last three decades whereas this trend has 
not been seen in SC pregnancies. The reason for this trend is not known and could 
only partly be explained by the increasing use of blastocyst transfer as discussed by 
the authors (Petersen et al., 2020). In regards of placental abruption we found a 1.6-
folded risk following blastocyst transfer in comparison to cleavage stage transfer, 
contradictory to other studies (Fernando et al., 2012, Ishihara et al., 2014, Oron et 
al., 2015). Placental abruption, a clinical diagnosis, is even harder to diagnose than 
placenta previa. Several risk factors including advanced maternal age, multiparity, 
smoking, HDP and previous Cesarean section exist (Baumann et al., 2000, Tikkanen 
et al., 2006a, Tikkanen et al., 2006b). Regarding both placenta previa and abruption, 
we were only able to partly adjust for the confounders mentioned which is also the 
case in other studies listed above.  
 
 
Blastocyst transfer: HDP and PPH 
In paper I, we found no association between extended culture and the risk of 
preeclampsia neither in comparison to cleavage stage pregnancies nor SC. Similar 
findings have also been observed in other studies on blastocyst transfer compared to 
cleavage stage transfer (Fernando et al., 2012, Oron et al., 2015). Neither has any 
differences been seen for pregnancy induced hypertension (Ishihara et al., 2014). 
PPH, defined as a postpartum bleeding of >500mL or >1000mL depending on 
country, is the leading cause of maternal mortality, not least in developing countries. 
For Sweden, the definition used is > 1000mL. Several risk factors for PPH exist, 
among them ART and a meta-analysis have reported on a 1.3-folded risk for PPH 
following an ART pregnancy in comparison to a non-ART pregnancy (Qin et al., 
2016). In our study, we found no association between blastocyst transfer and PPH, 
findings in line with a previous Australian study (Fernando et al., 2012).  
 
 
Frozen embryo transfer: HDP 
For autologous oocytes, a higher risk of HDP have been shown in singleton ART 
pregnancies when compared to singleton pregnancies following SC with the highest 
risks following FET (Pandey et al., 2012, Opdahl et al., 2015). Considering the trend 
 





towards FET, including the freeze-all strategy, this is a reason for concern. The 
reasons behind these findings are yet to be understood.  
 
The etiology behind preeclampsia is not fully elucidated, though thought to be 
multifactorial. Nonetheless, an inadequate placentation is crucial for the 
development. In ART pregnancies, an asynchrony between the endometrium and the 
embryo could potentially result in inadequate placentation leading to a higher 
incidence of HDP in ART pregnancies. Also placental oxidative stress and 
subsequently, a generalized inflammatory response (Myatt and Cui, 2004, Redman 
and Sargent, 2010, Pereira and Martel, 2014) have been discussed as contributors.  
 
Four recent studies, investigating the association between physiological changes 
during pregnancy and pregnancy outcome to the presence/absence of CL revealed 
increased risks for abnormal vascular adaptation and preeclampsia in pregnancies 
lacking a CL (von Versen-Hoynck et al., 2019, von Versen-Hoynck et al., 2019, von 
Versen-Hoynck et al., 2019, von Versen-Hoynck et al., 2020). The CL produces not 
only estrogen and progesterone but is also the sole source of relaxin in early 
pregnancy. Since relaxin plays an important part in vasodilation, consequently the 
absence of a CL might yield inappropriate vascular adaptations in early pregnancy. 
The results from the studies by von Versen-Höynck et al. are supported by our 
findings revealing an increased risk of HDP in programmed cycles both compared to 
natural (AOR 1.78, 95% CI 1.43-2.21) and stimulated cycles (AOR 1.61, 95% CI 
1.22-2.10) (paper II). Similar results have then also been confirmed in a large 
Japanese register-based study comparing outcomes in natural and hormone 
replacement cycles. In a sensitivity analysis, restricting the analysis to singletons, the 
results remained significant (Saito et al., 2019).  
 
In this thesis, oocyte donation pregnancies were excluded since they differ from ART 
pregnancies with autologous oocytes and poses different risks. However, the findings 
of adverse outcomes in programmed cycles, reminding of oocyte donation 
pregnancies with lacking CL, are interesting. Oocyte donation pregnancies have been 
thought to be more prone to adverse outcome due to immunological reasons, with a 
pregnancy immunologically completely foreign to the mother in case of an unrelated 
donor. Since oocyte donation pregnancies are primarily offered to women with 
premature ovarian failure and thus lacking a CL, the adverse outcome, similar to that 
of programmed cycles, might at least partly be explained by the absence of CL rather 
than by immunological responses.  
 
 





The novel findings by von Versen-Höynck and her research team, supported by 
results in our study as well as in the Japanese study by Saito et al. (2019), should 
enhance further studies on the mechanisms underlying the association between 
obstetric outcome and endometrial preparation. In regards of these results, at date, 
programmed cycles ought only to be used in women when ovulation fails.  
 
 
Frozen embryo transfer: Placenta previa and PPH 
Frozen transfer has been shown to have a potential protective effect on placenta 
previa. In paper II and III we reported on significantly lower risks of placenta previa 
in frozen cycles compared to fresh cycles (AOR 0.38 and AOR 0.35, respectively), 
findings that are in line with a previous Swedish study (Sazonova et al., 2012) as 
well as a meta-analysis (Sha et al., 2018). The cohorts in our study and the study by 
Sazonova et al. are partially overlapping. However, another systematic review and 
meta-analysis did not show any differences in the incidence of placenta previa 
depending on cycle type (Roque et al., 2019). In the meta-analysis by Sha et al. 
showing a lower risk of placenta previa in frozen cycles, six studies were included 
with a total of 72,000 pregnancies whereas the meta-analysis by Roque et al. included 
four studies and a total of 69,000 pregnancies revealing similar rates in the two 
treatment modalities. Three of the four studies in the meta-analysis by Roque et al. 
were also included in the study by Sha et al. Following different cycle regimens in 
FET, we did not see any differences in the rate of placenta previa, findings that are 
supported by the large Japanese study (Saito et al., 2019). Interestingly, in the 
Japanese study by Saito et al. the risk of placenta accreta was 7-folded following a 
programmed cycle in FET when compared to a natural cycle and in the study by 
Ishihara et al., FET was associated with a 3-folded increase in risk for placenta 
accreta in comparison to fresh transfer (Ishihara et al., 2014, Saito et al., 2019). 
However, placenta accreta is a rare outcome, the results have limited precision and 
should thus be taken with caution.    
 
On the other hand, for PPH, FET seems to be associated with an increased risk 
(Sazonova et al., 2012, Sha et al., 2018). In our study comparing different endometrial 
preparation methods used in FET, PPH was shown to be more common in 
programmed cycles in comparison to natural and stimulated cycles with almost 20% 
of pregnancies in programmed cycles yielding a bleeding >1000mL. When comparing 
all frozen cycles to fresh cycles and SC, the rate of PPH was moreover higher 
following a frozen transfer. These findings could be due to the increased risk of post 
 





term birth in especially programmed cycles leading to more induction of labor. 
Moreover, the increased risk of PPH could be attributable to larger babies.  
 
Frozen embryo transfer: Freezing techniques and maternal outcome 
Today, there is no evidence that the freezing technique would affect the rate of HDP 
as shown in paper III, a result that is supported by a small Swedish study (Wikland 
et al., 2010). For other maternal outcomes, no significant differences were seen in 
the risk of placenta previa, placental abruption and PPH comparing the vitrified 
blastocyst versus the slow frozen cleavage stage group. However, due to the sample 
size, precision is limited meaning that there might be a clinically relevant difference 
which this study could not identify. 
 
 
Preimplantation genetic testing and maternal outcome 
In our study, we found no differences in maternal outcome following PGT as opposed 
to IVF/ICSI. Few studies have investigated maternal outcome following PGT. In a 
small study from the United States on singletons there were no differences in placenta 
related complications and HDP (Hasson et al., 2017). However, in another study from 
the United States a 3-folded risk of preeclampsia was found following PGT in 
comparison to IVF/ICSI (Zhang et al., 2019). Yet, 70% of transfers in the PGT and 
IVF/ICSI group were performed in frozen cycles, a confounder not adjusted for. In a 
sub-analysis, only including frozen transfers, there was no difference in the rate of 
preeclampsia between women who have undergone PGT with IVF and women who 
have only undergone IVF. In our study, showing similar risks for HDP between the 
groups, only 30% of transfers were performed in frozen cycles and adjustment was 
made for fresh/frozen cycle. Altogether, at date, there is no evidence that the embryo 
biopsy per se would have any effect on maternal outcome.   
 
 
In summary, not only ART but also the advanced technique chosen might influence 
placentation. Blastocyst transfer seem to be associated with abnormal placentation in 
terms of increased risks of placenta previa and eventually also placental abruption 
whereas FET seems to be protective against placenta previa, yet increase the risk of 
HDP especially in programmed cycles. The freezing technique or the embryo biopsy 









5.3 General discussion 
In general, the majority of children born through ART are healthy and even though 
the maternal risks are increased in ART pregnancies the absolute risks are still low. 
The adverse effect on neonatal and maternal outcome following ART is, however, 
well known. Nonetheless, the reasons behind these findings are not fully elucidated. 
The infertility per se as well as the technical aspects have been suggested as 
contributors for the adverse outcome. The infertile population comprise a unique 
study population and hence picking out the optimal control population is a challenge. 
In the majority of studies performed, including the studies in this thesis, a healthy 
background population with a spontaneously conceived pregnancy have been used 
as the comparison group making it hard to distinguish whether the adverse outcomes 
observed in the children are a result of the infertility treatment, or rather the 
underlying infertility that indicated treatment. One way to overcome the problem 
concerning controls might be sibling studies comparing children born following SC 
and ART in the same mother. Another possible way is to establish a sub fertile 
control group with a spontaneous pregnancy but with a time to pregnancy for 
example >1 year. Such studies indicate that both maternal characteristics and the 
technique per se contribute to the adverse neonatal and maternal outcome 
(Romundstad et al., 2006, Romundstad et al., 2008, Henningsen et al., 2011, Luke 
et al., 2016, Luke et al., 2017, Zhang et al., 2019). One might though hypothesize 
that the patients in sibling studies comparing ART and SC pregnancies as well as in 
a sub fertile control group suffer from less severe infertility and are thus not 
representative for the general ART population. In paper I and II we have adjusted for 
years of involuntary childlessness, however, this variable is missing in a very large 
proportion of the SC group but also for 20-25% of women having ART treatment. 
The missing values for the spontaneously conceived women could be interpreted as 
no involuntary childlessness but could also be due to the question not being asked at 
the maternity unit. In several published studies, no adjustment for years of 
involuntary childlessness has been made. 
 
In addition, other parental characteristics differ between the groups, IVF parents 
usually being older, having lower parity and higher socioeconomic status, factors 
that also need to be accounted and adjusted for. Moreover, paternal characteristics 
could influence the outcome (Oldereid et al., 2018), confounders that are very rarely 
adjusted for in studies on ART outcome. There is also evidence that the diagnosis 
behind infertility on its own can alter the outcome. Endometriosis has been shown to 
alter perinatal and maternal outcome irrespective of ART or not (Stephansson et al., 
 





2009, Lalani et al., 2018). PCOS, another common reason for infertility treatment, 
also alters the outcome irrespective of age, BMI or ART (Roos et al., 2011). In 
Sweden, but presumably also abroad, infertility treatment is sometimes offered 
following minor infertility investigation and hence the cause of the underlying 
infertility is not available and thus impossible to take into consideration.  
 
Epigenetic changes are changes in the gene expression without changes in the DNA, 
i.e. a change in the phenotype without a change in the genotype. Epigenetic 
programming is a natural occurrence in both gametogenesis and during early 
embryonal development. Epigenetic modification can be influenced by age, lifestyle 
factors and diseases but also due to altered hormonal environment and manipulation 
of the oocytes, sperm and early embryos as shown in animal studies (Doherty et al., 
2000, Grace and Sinclair, 2009, Market-Velker et al., 2010, Mainigi et al., 2016). In 
recent years epigenetic differences in gene expression have been reported in 
frozen/thawed embryos. A previous study on mice have shown loss of methylation 
in genes responsible for growth following transfer of fresh and vitrified embryos with 
a greater loss in the vitrified embryos leading to normalization of gene expression 
(Wang et al., 2010). Other studies support these findings by showing that frozen 
embryos in human present epigenetic patterns more similar to natural conception 
(Estill and Krawetz, 2016, Ghosh et al., 2017). Furthermore, a recent meta-analysis 
showed an association between birth weight and DNA methylation (Küpers et al., 
2019). Whether epigenetic modifications related to methylation of genes in the 
human fetus and the maternal tissue during ART alters fetal growth and placentation 
and to what extent, however, needs further investigation.  
 
For singleton IVF pregnancies in general, the rate of birth defects seems to be 30-40%, 
or even up to 70%, higher as compared to SC, according to a number of systematic 
reviews and meta-analyses (Pandey et al., 2012, Hansen et al., 2013, Qin et al., 2017, 
Zhao et al., 2020). Interestingly, one paper suggests a larger difference in singleton 
pregnancies if excluding minor anomalies (Hansen et al., 2013). In our studies, paper 
I, II and IV, we found no differences when comparing singletons born following 
advanced techniques in ART to SC. Reasons for these results might be differences in 
study size and patient characteristics. In addition, the prevalence of birth defects in 
different regions of the world seem to differ due to unknown reasons, also a possible 
contributor to differences in results depending on study population (Qin et al., 2017). 
Unfortunately, there is no universal definition of major birth defects and in the majority 
of studies major and minor defects have been lumped together. The EUROCAT 
classification system, described in the Material and Method section, is updated with 
 





regularity and differentiates between major and minor birth defects, excluding all 
minor defects (www.eurocat-network.eu). To enable adequate comparisons and 
meta-analyses it is desirable that major birth defects would be reported according to 
EUROCAT in future studies. There are several reasons for only reporting on major 
birth defects in studies comparing ART and non-ART offspring. Children born 
following ART might be more closely examined due to parental anxiety, increasing 
the detection of minor anomalies. Moreover, it is assumed that major birth defects are 
more consistently reported whereas reports on minor are often more incomplete. 
Furthermore, major birth defects have more clinical relevance and the inclusion of 
minor birth defects could ultimately hide potential associations of ART and major birth 
defects. In addition, it is important that information on birth defects is collected in the 
same way for all groups, preferably via medical records and registers, not through 
parents by e-mail or phone calls. In paper II and IV we classified birth defects 
according to EUROCAT whereas in paper I, we used the same classification system 
as Källen et al. including all ICD 10 codes beginning with a Q but with exclusion of 
minor defects with little clinical relevance as described in the Material and Method 
section and also listed in the paper. The reason for this was to be able to compare our 
results to the results in Källen's study. In paper III all birth defects beginning with a Q 
according to ICD 10 codes were included, i.e. both major and minor birth defects. The 
reason for not categorizing major and minor birth defects in paper III was that we had 
no suspicions that the freezing technique per se would affect the rates.  
 
In Sweden, following 1999, termination of pregnancy due to birth defects should be 
reported to the Register of Birth Defects, however, according to a summary report 
from the register 35-50% of such terminations are not reported (the Swedish 
Pregnancy Register, Annual report Register of Birth Defects, 2018). Due to legal 
regulations on abortions in Sweden, these reports have only included the mothers date 
of birth, not the PIN, and can thus not be cross-linked to health and quality registers. 
One might assume that the diagnostics of birth defects as well as chromosomal 
abnormalities during pregnancy is more precise today than 10-20 years ago and in a 
recently published Nordic paper it was shown that the rate of birth defects has risen 
throughout the years, both following ART and SC, however the relative risk of major 
birth defects between ART and SC children remained unchanged. As suggested by 
the authors', the increase in birth defects is most likely explained by better data 
quality and better prenatal diagnostics (Henningsen et al., 2018). The terminations 
due to chromosomal abnormalities, especially trisomy 21, have more than doubled in 
Sweden between 1999 and 2016, yet no such trend has been seen for birth defects (the 
Swedish Pregnancy Register, Annual report Register of Birth Defects, 2018). In 
 





Sweden, legal abortion on own request is allowed prior to 18 weeks of pregnancy 
(≤17+6). During 18+0 and 21+6 legal abortion is allowed following written 
permission from the National Board of Health and Welfare due to special reasons 
including birth defects. Following infertility and an ART pregnancy, the inclination to 
terminate a pregnancy could be assumed to be lower if detecting a birth defect, which 
could influence the numbers and the analyses when comparing birth defects in ART 
and spontaneously conceived children. However, this has not been shown in studies 
from Finland and France, indicating similar rates on termination of pregnancies in 
ART and SC pregnancies (Pelkonen et al., 2014, Tararbit et al., 2015). 
 
Following blastocyst transfer and PGT a higher risk of PTB with AOR 1.2 and 2.0, 
respectively, was found in comparison to SC, results that are in line with several 
studies reporting on an increased risk of PTB (ORs/RRs 1.5-2.0) following ART 
(Helmerhorst et al., 2004, Jackson et al., 2004, McDonald et al., 2009, Pandey et al., 
2012, Qin et al., 2017). Moreover, ART singletons have been shown to be smaller 
(Helmerhorst et al., 2004, Jackson et al., 2004, McDonald et al., 2009, Pandey et al., 
2012, Qin et al., 2017). These findings are, however, particularly seen for fresh cycles 
whereas children born following FET are more often born post term and large as 
discussed before. The short- and long-term effects of being born small and preterm are 
widely recognized and described. These children are at a greater risk of birth asphyxia, 
CVD and metabolic syndrome (Osmond and Barker, 2000, Parkinson et al., 2013, 
Bellou et al., 2018, Wu et al., 2018). Whether these long-term effects are also 
attributable to ART children born small and preterm is less studied and needs large 
follow-up studies. On a short-term basis large babies are more likely to suffer from 
intrapartal asphyxia, hypoglycemia as well as labor and shoulder dystocia. The long-
term effects of being born macrosomic and LGA are less clear but some studies have 
shown an elevated risk of obesity and CVD (Ornoy, 2011, Gu et al., 2012, Derraik et 
al., 2020) as well as a higher risk for leukemia and Hodgkin's lymphoma (Roman et 
al., 2013, Crump et al., 2015, Petridou et al., 2015, Triebwasser et al., 2016, Groves 
et al., 2018). Given the fact that an increasing amount of ART cycles are performed as 
FET, large scale studies on the long-term effects are warranted. An unanswered 
question is also whether being born LGA but preterm, risks that might both be 
associated with extended culture (Martins et al., 2016, Alviggi et al., 2018) is better or 
worse than being born normal/small for gestational age, yet preterm.  
 
In comparison to spontaneously conceived pregnancies, ART pregnancies in general, 
independently of technique used, were associated with an increased risk of placenta 
previa (AOR 1.8-6.6, paper I, II and IV). For placental abruption, the difference was 
 





only significant when comparing blastocyst transfer and SC (paper I). Pregnancies 
following assisted reproduction are prone to more placental complications 
(Romundstad et al., 2006, Kallen, 2008, Healy et al., 2010, Vermey et al., 2019), a 
reason for concern considering the potentially detrimental effects on the health of both 
the newborn and the mother following both placenta previa and placental abruption. 
Sub fertility can be part of the explanation but the technique probably also matters as 
shown in a meta-analysis (Vermey et al., 2019), but also in a sibling study from 
Norway (Romundstad et al., 2006).   
 
In Sweden, the rates of Cesarean section are rather low compared to other parts of the 
world with a total rate of 17% in 2017 according to the MBR (MBR). For IVF 
pregnancies the rates are generally higher (25-33%) as shown in our papers. The 
reasons for this can probably be explained by several factors. The increased risk for 
PTB, small and large babies as well as placental complications might contribute. 
Moreover, patient´s and doctor´s anxiety, possibly higher in an ART pregnancy, might 
matter. Since infertility and/or ART treatment increases the risk of placenta previa as 
does Cesarean section, it is of great importance to avoid the first Cesarean section, not 
least in ART pregnancies.  
 
Choosing the optimal treatment is a challenge. A treatment leading to larger babies 
born at term, or possibly post term, and in parallel leading to more HDP but less 
placenta related complications? A treatment leading to possibly larger babies born 
preterm with a doubled risk for placenta previa? The answer is probably depending 
on person asked with different points of view from health care workers working in 
the reproductive field, obstetrics and neonatology. Nevertheless, it is important to 
keep in mind that all treatment options are not available for all patients and especially 
PCOS patients poses a challenge with a balance between excessive response with a 
high risk of OHSS and unexpected poor response with no embryos available for 
transfer. When choosing the best option for each woman/couple, consideration of 
risk factors such as medical history should be discussed thoroughly between the 
patient and the physician to enable individualized treatment.  
 
Even though pregnancies following ART are more prone to adverse perinatal and 
maternal outcome, most children are healthy and there has been a decline in the risk 
following ART as discussed in chapter 1.9, mainly depending on the decrease in 
multiple birth rate but probably also due to development and refinement of the 
technical procedures. As today, knowledge is though mainly based on observational 
studies and few RCTs have included neonatal and maternal outcome following ART. 
 





Yet, to study neonatal and maternal as primary outcomes following ART in RCTs, 
is hardly feasible. In conclusion, several possible factors, including parental 
characteristics, infertility treatment per se and sub fertility, contribute to the perinatal 
and maternal outcome following ART and potentially affects the long-term health of 
the ART children. In the future further epidemiological studies are warranted to study 
the long-term outcomes for the children and their mothers undergoing ART.     
 
5.4 Strengths and limitations 
The major strength in these nationwide population-based studies, is including large 
national birth cohorts of singletons conceived following different ART techniques 
and SC during the same time period. Information on outcomes were collected in 
similar ways for ART and spontaneously conceived children. In addition, data to the 
health and quality registers are primarily collected for quality reasons, not for the 
actual study, minimizing the risk of selection bias and re-call bias. Further, the 
number of children included in paper 1-III is large, yielding rather precise estimates 
for many outcomes and a possibility to discover even modest differences between 
groups. For paper IV, a national birth cohort of PGT children were included. Thus, 
low risk of selection bias and large sample sizes are the two most important strengths 




Yet, register-based studies also carry some limitations. Even though we were able to 
adjust for several confounders there is a risk of residual confounding of unknown 
and unmeasured confounders. Since the data is not collected for research purpose 
only and not by the researches themselves, important information might be lacking. 
One example of this is missing data on BMI. One might hypothesize that overweight 
(BMI >30) or obese (BMI >35) women do not want their BMI to be recorded. Since 
ART is generally not offered to obese women the missing data could cause a bias in 
favor for SC. In paper I, missing values on BMI were replaced by the overall mean 
whereas in paper II and III these women were excluded in the analyses. In paper IV 
BMI was not adjusted for. Another example is the lack of information on cause of 
infertility in the Swedish IVF register, thus this information was collected from the 
NPR. IVF is sometimes, however, performed following minor infertility 
investigation and therefore the diagnosis might be missing in the NPR. Moreover, 
 





data on medication used during ART treatment is not included in the Q-IVF and 
collected from the Prescribed Drug Register. In addition, in the included studies we 
have used a healthy background population as a control group while a sub fertile 
population with spontaneous pregnancies would have been more adequate since 
subfertility per se has been shown to have an impact on the outcome (Pinborg et al., 
2013, Luke et al., 2016, Luke et al., 2017). Such a group is hard to define, though. 
Finally, even though associations may be found in observational studies, causality 
can never be addressed.  
 
 
Strengths and limitations paper I 
The main strength in paper I is, apart from the population-based study design, the 
way we collected data on birth defects. This information was retrieved from three 
different sources, the MBR, the NPR and the Register of Birth Defects, and the 
follow-up time for the children was set to one year of age, minimizing the risk to 
miss any major birth defects. However, information on pregnancies leading to 
termination due to major fetal anomalies were not available, which is considered the 
main limitation in paper I.  
 
 
Strengths and limitations paper II 
In paper II, we were able to include all singletons born following frozen and fresh 
embryo transfer and SC and moreover divide the pregnancies in FET according to 
protocol used. However, since data on medication during ART treatment is not yet 
covered by Q-IVF, data on medication used was retrieved from the Prescribed Drug 
Register. We assumed that medication redeemed 70 days prior to ET belonged to the 
analyzed cycle, which is the major limitation of this study.  
 
 
Strengths and limitations paper III 
In this study, the main strength is combining two national birth cohorts in the Nordic 
countries, the Swedish and the Danish. The main limitation is investigating both the 
effect of freezing technique and culture duration at the same time, which makes it 
impossible to separate their effects on the outcome. Due to the rapid implementation 
of vitrification of blastocysts following the higher success rates (Stehlik et al., 2005), 
studies comparing perinatal and maternal outcomes between vitrified and slow-
frozen blastocysts are rare and hardly feasible.  
 





Strengths and limitations paper IV 
For the study on outcome following PGT, we included singletons born following 
PGT in Sweden since the birth of the first child and for as long as data were available, 
i.e. 1996-2017. The main limitation is the rather small sample size, which makes it 
impossible to adjust for all relevant confounders including fertilization method, 
culture duration and length of infertility. Moreover, the follow-up time is short for 
the majority of children especially in the PGT group lowering the absolute risks for 
diagnosis in early childhood.  
 
 
In conclusion, the large populations and minimizing selection bias by using national 
health registries are the main strengths of this thesis. Different techniques used in 
ART poses different neonatal and maternal risks.  
 
5.5 Ethical aspects of register-based research 
January 1, 2019 the Swedish Ethical Review Authority replaced the Regional Ethical 
Review Boards. The Ethical Review Authority is responsible for conducting ethical 
reviews of research on humans and consist of both researchers and nonprofessionals.  
 
The health registers run by the National Board of Health and Welfare include all 
citizens in Sweden and according to Swedish regulations individual patients cannot 
withhold or withdraw their medical data from the health registers, neither can they 
ask the data to be anonymized. The individual patient is identified using the unique 
PIN. Participation in the Swedish Quality Registers (www.kvalitetsregister.se) is not 
mandatory. However, by default, patients are presumed by the legislation to consent 
to registration but have the right to opt-out.  
 
For conducting register-based research in Sweden, ethical permission is required. 
Written consent from the patients is generally not required since it is assumed that 
the study participants do not object to research if it is accepted by the Ethical Review 
Authority. Several arguments for this manner exist. First, individual approvals would 
have a negative effect on the study size and statistical power. Second, in high-risk 
populations, one might hypothesize that consent would be difficult to obtain, thus 
causing a selection bias and a less generalizable result. A third reason is that some 
individuals would be dead by that time and consent impossible to obtain while a 
 





fourth reason is the increased costs for obtaining written consent for millions of 
individuals. Nevertheless, publication of data must guarantee the anonymity of the 
individuals and data should be presented at group level. This is particularly important 
for rare outcomes. Regarding rare outcomes, register-based studies with large study 
populations are needed to reveal any possible associations. However, it is important 
to weigh the statistically significant results against clinical relevance.  
 
In 2017, a Swedish report, based on surveys and interviews, found that the majority 
of the Swedish population is positive to the use of digital data in healthcare and 
research (Report ”For safety's sake”, 2017). In Finland, also a country with a tradition 
of health registers and offering a health care system very similar to the Swedish, 
similar results were found. In general, the participants were supportive of register-
based research. However, the opinion for informed consent was divergent and many 
would at least like to get information of the research use of their data (Eloranta and 
Auvinen, 2015).  
 
All studies in this thesis were approved by the Regional Ethical Committee at the 










Advanced techniques introduced in ART have increased success rates and the 
majority of children born following these techniques are healthy. In addition, the 
majority of women undergoing ART with advanced techniques do not suffer from 
pregnancy complications. Yet, some differences between techniques exist.   
 
➢ No increased risk of birth defects was found in singletons born after 
blastocyst transfer compared to cleavage stage transfer. The risk of 
placenta previa and placental abruption was higher in the blastocyst 
group as compared to the cleavage stage group. 
➢ In frozen/thawed cycles, an increased rate of HDP and PPH were 
detected in programmed cycles. Moreover, programmed cycles were 
associated with a higher risk of post term birth and macrosomia. 
Stimulated cycles had outcomes similar with natural cycles. The results 
suggest a link between the absence of corpus luteum in programmed 
cycles and adverse obstetric outcomes. These findings are important in 
view of the increasing use of frozen cycles including the freeze-all 
policy. 
➢ Transfer of vitrified blastocysts is associated with a slightly higher risk 
of PTB when compared with slow-frozen cleavage stage embryos. For 
other neonatal and maternal outcomes, no significant differences were 
found and at date, there is no indication that the freezing technique per 
se has major influence on the perinatal and maternal outcomes.  
Transfer of vitrified blastocysts compared to transfer of fresh 
blastocysts entails a higher risk of large babies, HDP and PPH, yet a 
lower risk of placenta previa.   
➢ There is no indication that the embryo biopsy used in PGT alters the 
perinatal, maternal or early childhood outcome. Singleton pregnancies 
following PGT had similar outcomes as IVF/ICSI pregnancies, yet a 
higher risk of PTB, LBW and placenta previa in comparison to SC. The 
limited data on early childhood outcomes is so far reassuring. 
However, there were only 267 PGT children included in the study and 
the mean follow-up time for these children was only 3.3 years.   
  
 













7 FUTURE PERSPECTIVES 
The reasons for the adverse outcome following ART are still not fully understood. 
Technical aspects, the underlying sub fertility, differences in parental characteristics 
as well as epigenetic changes following ART have been suggested as potential 
contributors. 
 
In the future, studies should focus on investigating the outcome according to the 
exposure since grouping all ART treatments together will create a very 
heterogeneous group, thus different techniques used in ART should be examined 
separately. Previously programmed and stimulated cycles in FET have been lumped 
together. The novel findings by von Versen-Höynck et al., suggesting a link between 
the presence/absence of CL and altered maternal outcome, shows the importance of 
not lumping all ART treatments in one group. These findings should enhance further 
studies on potential circulating compounds, such as relaxin or other yet unknown 
vasodilators, from the CL. Ultimately, adding relaxin in the luteal support regimen 
might be considered.  
 
Since the sub fertility per se has been shown to influence the outcome, sub fertility 
should also be accounted for, either by adjustment or by creating adequate 
comparison groups such as in sibling studies or creating a control group of sub fertile 
couples with for example time to pregnancy > 1 year. Other confounders that might 
be worth taking into consideration, yet seldom included/adjusted for in studies, are 
paternal characteristics influencing the outcome (Oldereid et al., 2018).  
 
According to the Barker-hypothesis, the intrauterine milieu has been shown to affect 
long-term health (Barker et al., 1993). Studies on the long-term consequences of 
ART treatment are still scarce and a large knowledge gap needs to be filled. The 
underlying reasons for the differences in long-term health might be attributable to 
the increased risks for adverse neonatal outcomes. Although some differences in 
long-term health have been described, the majority of ART children are healthy. 
 
In conclusion, quality and health registers offers a "goldmine" for further research 
on both short - and long- term consequences of ART. Since the technical 
development is fast, new advanced techniques introduced and the number of ART 
children born worldwide is steadily increasing, it is of great importance to continue 
the surveillance with large scale studies. The majority of the children born following 
ART are still rather young and follow-up on long-term consequences is thus 
warranted.   
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